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Chapter 1
Introduction
Longitudinal studies are common in medical research particularly in follow-
up studies where measurements on the same response variables of the subjects
(animals, humans, plants, etc) are obtained at specific observation times
(Tsiatis and Davidian, 2004). Longitudinal studies usually generates two
kinds of outcome.
Firstly, longitudinal studies generate repeated measurements of the same
variables at different time points. This results in each subject having a
response profile. For example, in a cohort study of subjects infected with
HIV, the CD4 count and viral load of each subject recruited into the study
were collected repeatedly at each visit day. Since the measurements are taken
from the same subjects, within subject correlation is inevitable. In order
to obtain valid results and make valid inferences from the analysis, special
statistical methods that take within subject correlation into consideration
will be required. Repeated measurements are often analysed using mixed
effect models. They model within subject correlation through the inclusion
of subject-specific random effects.
Secondly, another type of outcome measured in longitudinal studies is time
until the occurrence of a specific event. In this research, our specific event
of interest is death. Time until the occurrence of a specific event is typi-
cally analysed using survival analysis methods which includes the estimation
of the survival curve and models for the effect of covariates on the relative
hazard of the event of interest. Standard methodologies used in perform-
ing survival analysis focus on baseline covariates whose association with the
relative hazard does not change over time.
Figure 1.1 summarizes different methodological approaches for the two types
of responses. This dissertation will in particular focus on the analysis of
time-to-event responses.
1
2Figure 1.1: Illustration of the two response outcomes measured in longitudinal
studies and different methodologies used for analysing them.
In particular, the focus of this dissertation is to (1) look at methods available
to handle the association of baseline covariates with the relative hazard of the
event of interest where this association vary with time, (2) model the effect
of time-varying/ time-updated covariates. Therefore, the dissertation will
discuss (1) the standard Cox proportional hazard model, (2) how to model
time-varying effects of baseline covariates in the Cox model, (3) the extended
Cox model for time-varying covariates, (4) the joint model for incorporating a
time-varying effect in the Cox model and (5) the Aalen and semi-parametric
Aalen model used to estimate time-varying effects of covariates on survival.
These methods will be illustrated through the analysis of data from a cohort
of HIV infected subjects on HAART. The clinical objective is to investigate
the impact of treatment and CD4 on time to death.
The structure of this dissertation as shown in Figure 1.2 is as follows. In
Chapter 2, I will describe the dataset, its features and variables of interest
that will be used in this dissertation as well as perform some exploratory
analysis. The concept of survival models and analysis of time to event data
will be discussed in details in Chapter 3 while various methodologies for han-
dling time-varying covariates effects will be presented in Chapter 4. Chapter
5 presents results and interpretation of results obtained after using each of
the methodologies discussed in Chapter 4 on the dataset. By way of conclud-
ing, we will compare the results obtained from the different methodologies
3used in analysis the dataset and suggestions for future research will be made
in Chapter 6.
Figure 1.2: Dissertation Outline.
Chapter 2
Gugulethu Data
2.1 Introduction
This chapter gives brief description on how the data used for this research
were collected, defines the variables measured and carries out some exploratory
analysis on the variables of interest. The data collection procedure was ap-
proved by the University of Cape Town Health Sciences ethics committee.
In 2002, an Anti-Retroviral Treatment (ART) service was established in the
Cape Town township of Gugulethu. Data from all patients who initiated ART
within the programme between September 2002 and June 2007 were included.
HIV/AIDS patients who were eligible to receive ART service were referred
to the service from various primary health care clinics in the community.
The eligibility criteria was based on the National ART guidelines to provide
ART to those who have been diagnosed with AIDS or those whose CD4
count was less than 200 cells/µl. There is a median time of approximately
1 month between enrolment and the ART initiation by the patients. The
first-line treatment comprises of three antiretroviral medications (Stavudine,
Lamivudine and a reverse transcriptase inhibitor) together with prophylaxis
and infection treatment before and during the ART (Lawn et al., 2009).
Blood CD4 cell count and plasma viral load measurements were obtained at
baseline on entry into the study and thereafter 4 monthly, though exact visit
intervals varied. Other variables such as the patient’s age and gender were
obtained. If patients did not visit the clinic for consultation or to collect their
prescription for 12 weeks, they were considered as being lost to follow-up.
4
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2.2 Variable Description
Variables of interest that will be used for the data analysis are described
below.
1. PIDNo: Are unique identity numbers used in identifying the subjects
that were involved in the study.
2. Age: represents the baseline age of the subjects at registration into the
study in years.
3. Gender: represents the gender of the subject with 1 representing males
and 0 representing females.
4. Stage: denotes the World Health Organisation (WHO) Acquired Im-
mune Deficiency Syndrome (AIDS) stage with values ranging from 1
to 4. Stage 1 represents least severe and stage 4 represents full-blown
AIDS. The WHO guidelines define Stage 4 as having CD4 cell count
of less than 200 per micro-litre for adults and CD4 percentage of less
than 20% for children less than 5 years old, (WHO et al., 2005)
5. Treatment: represents the treatment status of a subject. 1 represents
the patient is on antiretroviral treatment and 0 that the patient is not.
6. CD4: represents the blood CD4 cell count values. They are usually
measured in cells per micro-litre of blood. They are used in accessing
how well one’s immune system is functioning or compromised. The
higher the CD4 cell count value of patients, the better.
7. Death: in this study, death is our event of interest. A patient that died
was coded as 1 and coded 0 if otherwise.
2.3 Data Exploration
This section discusses the distributions and summary statistic for each of
the variables in the data set. The complete data set contained 9152 subjects
with 818 patients that experienced the event of interest. The percentage
frequencies for the baseline categorical variables and the outcome in the data
set are reported in Table 2.1.
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Table 2.1: Frequency table for categorical variables in the Gugulethu data.
Variables Category Freq Percent
Gender Male (0) 2820 30.81
Female (1) 6332 69.19
Stage Stage1 3054 33.47
Stage2 1479 16.21
Stage3 3369 36.92
Stage4 1250 13.70
Death Yes (1) 818 8.94
No (0) 8334 91.06
Table 2.1 presents a frequency table which provides some summary statistics
for the categorical variables in the Gugulethu data. Out of 9,152 patients
involved in the study, a total of 818 experienced the event of interest which is
death. Of the 9,152 patients, 3054 of them are Stage1 HIV patients, 1479 are
Stage2 HIV patients, 3369 are Stage3 AIDS patients and 1250 are Stage4
AIDS patients. The variable Gender in Table 2.1 shows that 69.19% of the
subjects involved in the study are females.
Histograms were generated for the continuous variables, Age and CD4 and
are shown in the figures below.
The distribution of Age is approximately normal with a mean score of 32.98,
minimum and maximum values of 1.00 and 85.00 respectively.
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Figure 2.1: Histogram showing the distribution of Age.
7 2.3. DATA EXPLORATION
Figure 2.2 below shows the distribution of CD4. CD4 has a right (positively)
skewed distribution. Log and square root transformations succeed in bringing
in the tail as shown in Figures 2.3 and 2.4 respectively. In this research, the
log10(CD4) which will be represented as lCD4 will be used though it still
shows some right skewness.
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Figure 2.2: Histogram showing the distribution of CD4
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Figure 2.3: Histogram showing the distribution of lCD4
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Figure 2.4: Histogram showing the distribution of square root of CD4
The Kaplan-Meier survival curve is used in estimating the survival time of
individuals as well comparing the survival experience of two or more groups.
Hence, Figures 2.5 and 2.6, show the survival function for time to treatment
and the survival function of the whole HIV/AIDS cohort in the study re-
spectively. Details of the Kaplan-Meier estimator can be found in section
3.5.1.
In Figure 2.5, at time t = 0 months, no patient was on treatment but at time
t = 68 months, all the patients in the cohort under study had been placed
on treatment. The median time to treatment is about 27 months.
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Figure 2.5: Kaplan- Meier Curve for time to treatment.
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Figure 2.6 below is the Kaplan- Meier Curve showing the survival function of
the HIV/AIDS patients. There is a sharp decline corresponding to increasing
death rate at the start of the programme. This effect slows down but shows
an increase again after 60 months. At 60 months, the survival rate is above
85% showing the success of HAART.
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Figure 2.6: Kaplan- Meier Curve showing the survival function of the HIV/AIDS
patients.
Figure 2.7 below, shows the survival plots for 12 strata representing the
combination of three lCD40 categories namely < log(200), < log(200− 499)
and ≥ log(500) and four Age categories: 0-5, 6-19, 20-39 and 40-85. Strata
1 are individuals in the 0-5 years age category and have a lCD40 count of
less than log(200). Strata 2 are individuals in the 0-5 years age category
and have a lCD40 count between log(200− 499). Strata 3 are individuals in
the 0-5 years age category and have a lCD40 count greater than or equal to
log(500).
Strata 4 are individuals in the 6-19 years age category and have a lCD40
count of less than log(200). Strata 5 are individuals in the 6-19 years age
category and have a lCD40 count between log(200− 499). Strata 6 are indi-
viduals in the 6-19 years age category and have a lCD40 count greater than
or equal to log(500).
Strata 7 are individuals in the 20-39 years age category and have a lCD40
count of less than log(200). Strata 8 are individuals in the 20-39 years
age category and have a lCD40 count between log(200 − 499). Strata 9 are
individuals in the 20-39 years age category and have a lCD40 count greater
than or equal to log(500).
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Strata 10 are individuals in the 40-85 years age category and have a lCD40
count of less than log(200). Strata 11 are individuals in the 40-85 years
age category and have a lCD40 count between log(200− 499). Strata 12 are
individuals in the 40-85 years age category and have a lCD40 count greater
than or equal to log(500).
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Figure 2.7: Kaplan-Meier curves showing the number of events in each stratum
Chapter 3
Background
3.1 Introduction
This chapter gives a brief background about the concept and features of sur-
vival models. Basic notation used in survival analysis will be introduced.
In addition, different methods for estimating the survival function such as
the Kaplan-Meier estimator and Nelson-Aalen estimator will be discussed.
Regression models for modelling the effect of covariates on the hazard of an
event will be presented. The concepts of time-varying coefficients and covari-
ates will be introduced. Examples of each will be given and the differences
between both will be discussed. This chapter will give some intuition into
the main ideas underlying the methodology.
3.2 Survival Models
Survival analysis is a collection of statistical procedures for data analysis
for which the outcome variable of interest is the time until an event occurs
(Kleinbaum and Klein, 2010). Time refers to the period from the beginning
of follow-up of an individual until an event occurs or until censoring. These
could be in years, months, weeks, or days. On the other hand, event means
any designated experience of interest. The event of interest could be death,
disease incidence, relapse from remission or recovery (Kleinbaum and Klein,
2010). The Gugulethu HIV/AIDS study followed HIV/AIDS patients over
about 65 months until death or current end of follow up. The event of interest
is death, and the outcome is time in months until a person dies.
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3.3 Features of Survival Models
This section presents the features of survival models in terms of censoring
and the structure of survival data.
3.3.1 Censoring
An important feature to be considered in survival analysis is censoring. An
observation is censored when the event time for all the subjects in the study
is not fully known. Standard statistical tools such as sample mean, standard
deviation, t-test, linear and logistic regression cannot be used as they are
based on the assumption that the information used is complete (Rizopoulos,
2012).
There are basically three forms of censored observations: right, left and
interval censored observations. Right censoring which is the most common
form occurs when the complete survival time has been cut off at the right side.
That is, the event of interest was not observed due to study period expiration
or withdrawal of individual or lost to follow up. Interval censoring is a special
form of censoring as it incorporates both right-censoring and left-censoring.
An observation is said to be interval censored if the exact time the event
of interest occurred is unknown but it is known to have occurred within a
particular interval. An observation is left censored if the event of interest has
occurred before enrolment.
Conditional on the value of any covariates in a survival model and on an
individual’s survival to a particular time, censoring must be independent
of the future value of the hazard for the individual. Censoring that meets
this requirement is non-informative. A common instance of non-informative
censoring occurs when a study terminates at a predetermined date. If this
condition is not met, the estimates of the survival distribution can be seri-
ously biased. For example, if individuals tend to drop out of a clinical trial
shortly before they die, and therefore their deaths go unobserved, survival
time will be over-estimated.
Figure 3.1 below shows the study time of ten subjects. “•” represents the
start of follow up. The subjects were observed at times 0, 2, 4, 6, 8, 10
and 12 only. Subjects 1, 7 and 8 died (D) during the course of the study,
subjects 2 and 9 were lost to follow-up (L), subjects 3 and 6 were withdrawn
(W) from the study due to the negative effect the treatment had on them.
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Finally, subjects 4, 5 and 10 were still alive (A) at the end of the study. For
a study where the event of interest is death, subjects 4, 5 and 10 are said
to be right censored because the event of interest was not observed during
the course of the study due to administrative censoring in that the end of
follow-up was reached. In addition, subjects 3, 6 and 9 are also right censored
because the event of interest was not observed over the study period due to
withdrawal and loss to follow-up (LTFU). On the other hand, the subjects
1, 7 and 8 could be regarded as a interval censored observation because the
exact time the event of interest (death) occurred isn’t known since their death
would only be recorded at the scheduled visit following the actual death date.
However, we are aware it occurred within a particular interval.
Figure 3.1: Visual illustration of the different types of censoring.
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3.3.2 Structure of Longitudinal / Survival Data
Longitudinal data can be constructed or presented in two forms: (1) the
wide form which is basically when repeated responses from each subject is
recorded in a single row with each successive response recorded in a separate
column and (2) the long form, where repeated measurements at each time
point for each subject is recorded in a separate row. Variables whose value
do not change over time remain the same in all the rows for a given subject.
The choice of which form to present your data in is dependent on the type of
analysis to be carried out. If one is interested in performing survival analysis
for example, the required data format is the long form since multiple time
points per subject will allow time-varying characteristics to be captured.
In this section, we will describe the structure of survival data. The key
components of survival data are:
1. a unique subject identifier
2. time variable: which could be date, time. This variable stores the time
the event of interest was observed. It could be time to death, remission,
exacerbation etc.
3. Failure or event variable: this is an indicator variable with 1 if the event
of interest occurred and 0 if censored. This is applicable if we have only
one event of interest. In the presence of competing risk, the indicator
will have as many categories as the competing event categories.
The data structure when fitting the standard Cox proportional hazard (PH)
model is such that only the baseline observations on the covariates for each
subject is used. Hence, just one observation per subject including baseline
covariate values, total follow up time and an event indicator is necessary.
However, for models like the extended Cox used for time-dependent covari-
ates, we create several time intervals for each subject using the (start, stop]
notation. This means that all the changes that occurred in a covariate is
recorded at the stop time. Here, the structure of the data is the long format
with each subject’s observation recorded in multiple rows for a specific time
interval.
Figure 3.2 presents a subset of the HIV/AIDS dataset generated as a result
of repeated observations taken on some explanatory variables of interest that
will be used in this research. Subject 2 had a follow-up time from 0 to 26.46
months. The variable log CD4, (lCD4) is a time varying covariate and
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was measured each time the subject visited the clinic. The start and stop
variables denotes the time interval limits when the CD4 count was recorded.
For subject 2, the log CD4 equals 2.11 at baseline, 2.29 at 4.13 months, and
2.54 at 7.80 months and so on. The variable DEATH is an event indicator and
equals 1 if the subject died at the end of the corresponding time interval.
Variables like Age and Gender that do not change over time remains the
same for each subject.
Figure 3.2: Subset of the HIV/AIDS survival dataset generated as a result of re-
peated observations taken on some explanatory variables of interest.
3.4 Basic Concepts and Notation
This section presents a summary of the concepts and notations of survival
models discussed in (Kleinbaum and Klein, 2010) and (Collett, 2015). Let
T ∗i denote the true survival time for the ith individual, Ti be a non-negative
random variable which denotes an individual’s observed survival time, defined
as min(Ci, T
∗
i ). Ci the censoring time, δi = I(Ti ≤ Ci) the event indicator
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for the ith subject and t is a specific value of T. Let yi(t) be the observed
value of a time-dependent covariate at time point t.
3.4.1 Probability Density Function f(t)
The probability density function, f(t), the probability of death at time t, is
given by
f(t) = P (T = t).
= lim
∆t→0
Pr(t ≤ T ≤ t+ ∆t)
∆t
. (3.1)
3.4.2 Cumulative Distribution Function F(t)
The cumulative distribution function, F (t), the probability that the event of
interest has occurred on or before time t, is given by
F (t) = Pr(T ≤ t)
=
∫ t
0
f(u)du. (3.2)
3.4.3 Survivor Function S(t)
The survivor function,S(t), is the compliment of the cumulative distribution
function. It gives the probability of an individual surviving beyond the spec-
ified time t. This is a decreasing function with S(t) = 1 when t = 0 to
S(t) = 0 when t =∞,
S(t) = P (T > t) = 1− F (t)
= 1− P (T ≤ t)
= 1−
∫ t
0
f(u)du. (3.3)
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3.4.4 Hazard Function h(t)
The hazard function, h(t), gives the instantaneous risk at time t for the event
to occur, given that the individual has survived up to time t,
h(t) = lim
∆t→0
P (t ≤ T < t+ ∆t | T ≥ t)
∆t
. (3.4)
The hazard function is related to the survivor function in the following way:
S(t) = exp
[
−
∫ t
0
h(u)du.
]
(3.5)
h(t) = −
[dS(t)
dt
]
. (3.6)
Equation (3.5) shows that the survival function equals the exponent of the
negative of the integrated or cumulative hazard function whereas equation
(3.6) specifies the hazard function as the negative derivative of the survival
function.
(a) The survival function (b) The hazard function
Figure 3.3: Plots showing the survival and hazard functions.
As can be seen from Figure 3.3(a), the survival function is a decreasing
function. It ranges from 1 to 0. At time t = 0, the probability of a subject
surviving a particular condition is 1 (S(0) = 1), that is all the patients are
still alive. As time progresses, the probability of survival reduces and tends
towards 0 (S(∞) = 0), implying that all the patients have died. The survival
function is a step function because events are observed at discrete times.
Unlike the survival function that has an upper bound of 1, the hazard func-
tion does not have an upper bound. Figure 3.3(b) presents three different
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hazard functions. The hazard function can commence at any point and move
in any direction over time. When the hazard function is a straight line, it
is said to have a constant hazard. This implies that at any given time, the
value of the hazard function remains the same. Hence, a survival model is
said to have an exponential distribution if the hazard function is constant.
3.5 Survival and Hazard Ratio Estimation
In this section, I will discuss both parametric and non-parametric techniques
for estimating the survival and cumulative hazard function.
3.5.1 Kaplan Meier (K-M) Estimator
The K-M estimator was said to have been proposed by Bo¨hmer (1912) but
was not used until in 1958 when a paper was released by Kaplan and Meier
on the subject, (Andersen et al., 2012). The K-M estimator (Kleinbaum and
Klein, 2010) also known as the product limit estimator (the survival proba-
bility is limited to product terms up to the survival time being specified) is
a non-parametric (that is no underlying distribution is assumed) technique,
popularly used in the estimation of survival time. This technique takes into
account censored observations, especially the right censored observations.
This is achieved by assuming that subjects censored at time t survive longer
than the deaths at time t and no adjustment for the number at risk is re-
quired. At the next time point, the censored observations are removed from
the number at risk. The K-M estimator is computed as the product of sur-
vival estimates at successive time points. Let t1 < t2 < · · · tj be the time
the event of interest is observed, dj be the number of individuals that have
experienced the event at tj and rj is the number of individuals who are yet
to experience the event. It takes the form below:
Sˆ(t) =
∏
tj≤t
(
1− dj
rj
)
(3.7)
where
dj
rj
estimates the proportion of the dj that experience the event at time
tj of the rj exposed or under observation at time tj.
The variance is estimated using the Greenwood’s formula
σˆ2(t) = Sˆ(t)2
∑
tj≤t
dj
rj(rj − dj) . (3.8)
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The K-M survival curve can be used to illustrate the survival experience of
two or more groups. However, a statistical test is required to ascertain if the
difference between the groups are statistically significant or otherwise. There
are many options such as the log-rank test, the generalised Wilcoxon test, the
Peto’s generalised Wilcoxon test, the Tarone-Ware test and the Flemington-
Harrington test to access this difference. The choice of which test to use
depends on whether all failure times are treated with equal or differential
importance. The “log-rank test” is the most commonly used method. It
tests the null hypothesis that two or more survival functions are the same
but does not give an estimate of the difference between groups. This approach
gives equal weight to all deaths whereas other variants (generalised Wilcoxon,
Peto’s generalised Wilcoxon, Tarone-Ware and Flemington-Harrington test)
apply different weights at either the early or later time.
The log rank test statistic used to compare the survival function of two groups
is formed by using the squared difference between the summed observed
and expected scores for one of the groups divided by the variance of the
difference between the summed observed and expected scores. Under the
null hypothesis that two survival functions or curves are the same, the log
rank test statistic has an approximately chi-square distribution with one
degree of freedom. The log rank test for two groups takes the form below:
Z =
(Oi − Ei)2
var (Oi − Ei) . (3.9)
where,
Oi − Ei =
∑
f=1
(mif − eif ).
e1f =
(
n1f
n1f + n2f
)
× (m1f +m2f )
e2f =
(
n2f
n1f + n2f
)
× (m1f +m2f )
var (Oi − Ei) =
∑
j
n1fn2f (m1f +m2f )(n1f + n2f −m1f −m2f )
(n1f + n2f )2(n1f + n2f − 1) .
where,
Z denotes the log rank test statistics, i = 1, 2, Oi & Ei are the summed
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observed and expected scores for group i. eif is the expected number at time
f for the ith group. It is the proportion of individuals at risk multiplied by
the number of failures in both groups. mif and nif are the number of failures
and risks at time f for the ith group respectively.
3.5.1.1 Likelihood Estimation
According to Dobson and Barnett (2008), let yj be the response observa-
tion recorded for the jth subject, δj is event indicator with δj = 0 for cen-
sored event times and δj = 1 if the event of interest was observed. Let
y1, · · · , · · · , yr and yr+1, · · · , yn be the observations that are uncensored and
censored respectively and let xj denote the vector of explanatory variables.
The expression below is the likelihood function for the uncensored variables
r∏
j=1
f(yj).
The expression below is the likelihood function for the censored variables
n∏
j=r+1
S(yj).
The complete likelihood is
L =
n∏
j=1
f(yj)
δjS(yi)
1−δj . (3.10)
The log-likelihood function is expressed as
l =
n∑
j=1
[
δj log f(yj) + (1− δj) logS(yj)
]
.
=
n∑
j=1
[
δj log f(yj)− δj logS(yj) + logS(yj)
]
.
Recall that
f(yj)
S(yj)
= h(yj). Hence,
l =
n∑
j=1
[
δj log h(yj) + logS(yj)
]
. (3.11)
Parameter estimation is done using numerical methods such as the Newton-
Raphson approach to maximise the log-likelihood function.
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3.5.2 Nelson-Aalen Estimator
Aalen (1978, 1975) introduced the Nelson-Aalen estimator which is the gener-
alization of the empirical cumulative intensity estimator proposed by Nelson
(1969, 1972) and Altshuler (1970). It is a non-parametric estimator used in
estimating the cumulative hazard function for censored survival data (An-
dersen et al., 2012). Let t1 < t2 < · · · tj be the time the event of interest is
observed, dj be the number of individuals that have experienced the event at
tj and rj is the number of individuals who are yet to experience the event.
The Nelson-Aalen estimator is given by:
Aˆ(t) =
∑
tj≤t
dj
rj
. (3.12)
The variance of Aˆ is estimated by
σˆ2(t) =
∑
tj≤t
(rj − dj)dj
(rj − 1)r2j
. (3.13)
Thus, whereas the K-M estimator is multiplicative, the Aalen estimator is
additive. It can be shown that S(t) = exp[−A(t)] or equivalently, A(t) =
− lnS(t).
3.6 Regression Models
Whereas the above non-parametric estimators generate estimates of survival
and hazard functions, regression models are needed to measure the associa-
tion between several categorical and continuous covariates and the hazard or
survival functions. The logistic or multiple regression models are not appro-
priate in this situation as they do not account for censored observations.
There are two broad categories of regression models used in survival analysis.
They are the semi-parametric and parametric regression models. A model
is said to be semi-parametric if no distributional assumption is made for the
baseline hazard (this is the non-parametric bit) but the effect of predictors
assumes a parametric form (this is the parametric bit). The Cox proportional
hazard (PH) regression model is a common example of a semi-parametric
model. On the other hand, parametric models are models in which the hazard
function has an underlying distribution. The class of parametric models can
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be divided into the proportional hazard (PH) models and accelerated failure-
time (AFT) models.
In the PH regression model, the effect of covariates is obtained on the hazard
function and covariates act multiplicatively on the hazard. Common para-
metric PH models include the exponential, Weibull or Gompertz models.
The general form of a semi-parametric PH models is given below:
hi(t) = h0(t) exp(β1Xi1 + β2Xi2 + · · ·+ βpXip) (3.14)
where,
h0(t) is an arbitrary baseline hazard rate, reflecting the hazard rate when
all X’s = 0. Xi1, · · · , Xip are the p-covariates or risk factors of interest and
β1, · · · , βp are regression coefficients estimated, by maximizing the partial
likelihood.
The semi-parametric Cox PH model is obtained when no underlying dis-
tribution is assumed for the baseline hazard function. However, when the
baseline hazard function is assumed to follow a distribution, the parametric
PH model is obtained.
We will focus on the non-parametric Cox proportional hazard model in this
dissertation. It will be discussed in details in section 4.2.
Chapter 4
Methodology
4.1 Introduction
This chapter presents a review of the Cox proportional hazards (PH) model
(which is popularly used in analysing time to event data) and the techniques
used in estimating the parameters. In addition, we review various model
diagnostics to ascertain the adequacy of the model fit. However, this model
is based on the PH assumption. Violation of PH assumption often leads to
biased results and inferences. Once non-proportionality is established, there
is need to consider time-varying effects of the covariates.
Several models have been developed that relax the proportional hazard as-
sumption making it possible to analyse data with time varying effects of
both baseline and time-updated covariates. Various approaches for handling
time varying covariates and time-varying effects in time to event models will
be discussed. They include the stratified Cox model and the extended Cox
model which handles exogenous time-dependent covariates using the count-
ing process formulation introduced by Andersen and Gill (Rizopoulos, 2012).
Another is the Aalen model, an additive model which easily accounts for time-
varying effects. However, there are situations where not all the covariates
of interest have time-varying effects. Hence, the semi-parametric additive
model is used. The Cox-Aalen model is an alternative model which combines
Cox proportional hazards model for covariates with constant effects and the
Aalen additive model for time-varying effects in a single model. Finally, we
will consider joint models for longitudinal and time-to-event processes.
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4.2 The Cox Proportional Hazards (PH) Model
Cox (1972) in a seminal paper introduced the Cox proportional hazards re-
gression model. It is the most popularly used model in analysing survival
data. This model is used in describing the hazard function of an event of in-
terest as a function of multiple prognostic factors thereby adjusting for other
covariates unlike in the K-M approach. In this section, we will discuss the
form of the Cox PH model, what the PH assumption entails and estimation
of the model parameters.
4.2.1 The Cox Proportional Hazards Model Form
The Cox proportional hazards model is of the form:
h(t,X) = h0(t) exp
(
Xβ
)
.
= h0(t) exp(β1Xi1 + · · ·+ βpXip).
(4.1)
where,
h0(t) is an arbitrary baseline hazard rate, reflecting the hazard rate when
all X’s = 0. Xi1, · · · , Xip are the p-covariates or risk factors of interest and
β1, · · · , βp are regression coefficients, estimated by maximizing the partial
likelihood.
Equation 4.1 is basically the product of the arbitrary baseline rate and the
exponential expression of a linear combination of the covariates. Hence, it is
referred to as a multiplicative model. Taking the exponent of the estimated
regression coefficient (e(βˆ)) provides a hazard ratio estimate. For categorical
variables, a hazard ratio greater than 1 (β > 0), implies there is an increased
risk of the event of interest occurring for the subjects in one category com-
pared to the subjects in the reference category, while a hazard ratio lower
than 1 (β < 0) indicates a decreased risk. In the case of a continuous variable,
a hazard ratio greater than 1 (β > 0) indicates an increased risk associated
with a unit increase in the covariate while a hazard ratio less than 1 (β < 0)
indicates an decreased risk for a unit increase in the covariate.
The following admirable properties account for the popularity of this ap-
proach. Firstly, it is a semi-parametric model, that is, no distribution is
assumed for the baseline hazard function. Secondly, it is a “robust” model,
results obtained from the Cox PH model are similar to the results from the
correct parametric model. Thirdly, in the absence of covariates in the model,
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the Cox PH reduces to the baseline hazard function. The baseline hazard
function is the hazard function obtained when all the covariates in a model
are zero. Fourthly, the set up of the model, specifically the exponential ex-
pression ensures that the estimated hazards are always positive. Fifthly,
the regression coefficients in the model can be estimated irrespective of not
assuming any distribution for the baseline hazard function. Without esti-
mating the baseline hazard function, the measure of effect (hazard ratio) can
be obtained.
Despite the admirable properties of the Cox PH model as listed above, it is
based on the underlying proportional hazard assumptions.
4.2.2 The PH Assumption
A fundamental underlying assumption of the Cox PH model is that of pro-
portional hazards. The PH assumption requires that the hazard ratio is
constant over time, that is, the hazard ratio is time independent. Suppose
that the event of interest is death, and we are interested in its association
with p covariates, X1, X2, · · · , Xp, then the hazard for a given set of values
for these covariates is given by:
h(t) = h0(t) exp(β1x1 + β2x2 + · · ·+ βpxp).
Assume that we are interested in a single covariate then the hazard is:
h(t) = h0(t) exp(βx).
The hazard ratio of two subjects with covariate values x1 and x2 is expressed
as:
HR =
hx2(t)
hx1(t)
= exp[β(x2 − x1)]. (4.2)
Equation 4.2, shows that the hazard ratio (which compares two subjects who
differ with respect to their value for X by x2 − x1) is constant. This implies
that it is independent of time(t).
From Equation 4.1 we observed that the baseline hazard function is a function
of time only whereas the exponential expression is a function that includes
Xi and βi alone. However, there could be situations whereby either the Xi’s
or/and the βi’s is a function of time.
26 4.2. THE COX PROPORTIONAL HAZARDS (PH) MODEL
The X’s are referred to as time-independent variables because their values
do not change over time. However, there could be situations whereby the
X’s are functions of time. These types of variables are referred to as time
dependent variables. When the βi’s depend on time, the Cox proportional
hazard assumption has been violated. Hence, using the Cox PH model will
be inadequate. Other models such as the stratified and extended Cox models,
amongst others could be used.
4.2.3 Model Estimation
Fitting the Cox proportional hazards model to a set of observed data requires
the estimation of both the baseline hazard function and the unknown regres-
sion coefficients. However, both components can be estimated separately.
This section, will only present how the regression coefficients are estimated.
Regression coefficients, β’s, of the Cox proportional model are estimated
using the maximum likelihood approach. A likelihood is basically the joint
probability of the data that was observed and it’s treated as a function of the
unknown parameters in the model. The aim is to find the set of parameter
values that maximises the likelihood function. It has been observed that it is
computationally easier to maximise the logarithm of the likelihood function.
The log-likelihood is maximized using the numerical methods such as the
Newton-Raphson method.
Suppose n subjects have t1, t2, · · · , tn as their event times with the ordered
event times of r individuals as t1 < t2 < · · · < tr. Let t(i) be the ith ordered
event time. R(t(i)) is said to be the number of subjects at risk at time t(i).
The partial likelihood function for the Cox proportional hazards is given by
L(β) =
r∏
i=1
exp(β′x(i))∑
l∈R(t(i)) exp(β
′xl)
. (4.3)
where x(i) is a vector of covariates for subjects that died at the i
th ordered
event time, t(i). Equation 4.3 considers uncensored observations only. That
is, only subjects that have either observed the event of interest or those that
are at risk. This is evident in equation 4.3 as the denominator is summed
over the subjects yet to experience the event of interest. However, event
times of censored subjects contribute to the risk set but this is just before
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they are censored. In addition, the product is over the subjects whose event
times are known.
Suppose n subjects have t1, t2, · · · , tn as their observed event times and δi is
the event indicator with its value being 0 if the ith event time is censored and
1 otherwise. δi is used as an exponent because it is a suitable way of getting
all the observations included in the likelihood function without excluding the
event times. The likelihood function in 4.3 can then be expressed as
=
n∏
i=1
{
exp(β′x(i))∑
l∈R(t(i)) exp(β
′xl)
}δi
. (4.4)
with R(t(i)) being the risk set at time ti. Since δi is 0 if the ith event time
is censored and 1 otherwise. It implies that censored observations do not
contribute to the likelihood function (recall the laws of indices: anything to
the power of zero = 1).
Equation 4.5 below presents the log-likelihood function.
logL(β) =
n∑
i=1
δi
{
β′xi − log
∑
l∈R(t(i))
exp(β′xl)
}
. (4.5)
4.2.4 Model Diagnostics for the Cox Regression Model
Most models are based on assumptions. Hence, diagnostic techniques are
used in determining whether the fitted model describes the data adequately.
In addition, the validity of those assumptions are checked and ways in which
they are being violated are identified. This implies studying and investigating
certain aspects of the model fit such as the selection of explanatory variables
to be included in the model, functional forms of the variables, outlying and
influential observations and verifying that the PH assumption is satisfied.
Residuals are commonly used in assessing specific aspects of model adequacy.
Some of the residuals defined for the Cox regression model are the scaled
Schoenfeld residuals, used to verify the violation of the proportionality as-
sumption. The Cox-snell residuals will be used in examining the overall fit
of the model. The Martingale residuals are used to determine the functional
form of a covariate. The dfbeta statistics are used in determining influential
observations.
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4.2.5 Cox-Snell residuals
According to Cleves (2008), Cox-Snell residuals are used in checking the
overall fit of a model. A model fit is considered as being satisfactory if
the estimated survival function for the kth individual at time t, (Sˆk(tk)), is
similar to the observed/true survival function for the kth individual at time
(Sk(tk)). In addition, when an appropriate model has been fitted, Cox-Snell
residuals are assumed to have an exponential distribution with unit mean.
This means that the slope of the cumulative hazard should be 1 (i.e. 45◦
angle). The Cox-Snell residual for the kth individual, is given by
rCk = exp(βˆ
′
xk) Hˆ0(tk), (4.6)
where Hˆ0(ti) is the estimated cumulative baseline hazard, this is also known
as the Nelson-Aalen estimator. The major drawback of the Cox-Snell resid-
uals are that they do not highlight the reason why the model does not fit the
data.
4.2.6 Martingale residuals
The Martingale residuals are used in examining how necessary each of the
covariates included in the model are. In addition, it is used to ascertain
whether the functional forms of the covariates in the model are appropriate.
If the functional form of the covariates are inappropriate, a transformation
of covariates may be appropriate. The expression for the martingale residual
is given below:
Mˆk(t) = δk − rCk, (4.7)
where,
rCk is the Cox-Snell residual and δk is the observed number of deaths for the
kth individual in the interval [0,t] with δk = 0 if the survival time is censored.
From Equation 4.7, martingale residuals at each time t can be defined as
the difference between the observed number of deaths for the kth subject
in the interval [0,t] and its corresponding estimated number of deaths on
the basis of the fitted model. Properties of this residuals under the correct
model specifications include: (1) the residuals sum up to zero at any given
time point i.e
∑
Mk(t) = 0, (2) martingale residuals have an expected value
of zero, E(Mˆk(t) = 0), (3) the residuals are uncorrelated with one another,
cov(Mˆk, Mˆj) = 0, (4) martingale residuals takes values between −∞ to 0.
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4.2.7 Deviance residuals
Therneau et al. (1990) proposed the deviance residuals due to the limita-
tions and disadvantages of the martingale residuals; its heavy skewness and
interval values that makes the identification of outlying observations difficult.
Deviance residuals are basically martingale residuals that are rescaled to give
a symmetrical distribution about zero. They are used in identifying outlying
observations. The deviance residual for the Cox regression model is defined
below as
dj = sgn(Mˆk)
[− 2{Mˆk + δk log (δk − Mˆk)}] 12 , (4.8)
where
Mˆk = the martingale residual of the kth subject.
sgn = the signed function.
Equation 4.8 is intuitive as the value of the deviance residual can be zero
only if Mˆi = 0. In addition, the value of the martingale residual is increased
to be closer to one by the log function whereas the square root function tends
to shrink large negative values (Therneau et al., 1990).
4.2.8 Dfbeta statistics
Dfbeta statistics are used for detecting influential observations. They do this
by measuring the degree to which the regression coefficient changes or is af-
fected if the ith observation were deleted. Each subject i has one dfbeta value
for each covariate in the model. This change is measured in terms of the stan-
dard deviation units. An observation is said to have a considerable amount
of influence on the jth regression coefficient if it has large dfbeta values. In-
fluential positive (negative) dfbeta values increases (decreases) the regression
coefficient (Braun, 2011). Equation 4.9 represents the dfbeta statistic .
∆βj,i =
βˆj − ˆβj(i)
S2(i)Cjj
, (4.9)
where,
Cjj is the j
th diagonal element of (X ′X)−1, βˆj is the jth regression coefficient
from the whole data set. ˆβj(i) is the j
th regression coefficient obtained when
the ith observation is removed and S2(i) is the mean square error.
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Note that
∆βj,i >
{
1 for small n
2√
n
for large n
(4.10)
serves as a guideline for deciding whether observations are influential or not.
In situations where there are influential observations, it might be necessary
to perform sensitivity analysis, that is present results with and without the
influential observation(s). When it is obvious that error in data entry is the
reason for the influential observation(s), they could be deleted permanently.
4.2.9 Schoenfeld residual
Schoenfeld (1982) proposed the Schoenfeld residuals also known as partial
residuals which is used in investigating if the proportional hazards assump-
tion holds. The Schoenfeld residual at time t is the difference between the
observed value of the ith explanatory variable for the kth individual and
its conditional expectation given the set of all individuals at risk at time tk
(Fitrianto and Jiin, 2013). This is given by
rˆki = Xki − Eˆ(Xki|Rk), (4.11)
where
Eˆ(Xki|Ri) =
∑
l∈R(tk) Xil exp(β
′Xl)∑
l∈R(tk) exp(β
′Xl)
.
The estimates of β are obtained by maximizing the partial likelihood func-
tion. Schoenfeld residuals are time independent. If the proportional hazard
holds, a plot of the kth residual(rˆki) against tk should be centered around
zero and should have a random pattern.
(Grambsch and Therneau, 1994) suggested the scaled Schoenfeld residual are
obtained by multiplying the covariance matrix of the residuals by the vector
of the partial residuals. This approach has been proven to yield residuals
with greater diagnostic power when compared to the unscaled Schoenfeld
residual (Fitrianto and Jiin, 2013).
rˆ∗k = [V ar(rˆk)]
−1rˆk, (4.12)
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where,
rˆ∗k is the scaled Schoenfeld residual and rˆk is the Schoenfeld residual proposed
by Schoenfeld.
4.3 Time-varying effects (or coefficients)
The effect of covariates on the hazard of an event of interest occurring could
vary over time. This is reflected in terms of regression coefficients that vary
over time. In section 4.2.2, we discussed the PH assumption, which assumes
that covariates regression coefficient remain the same over time, that is β(t) =
β. For time-varying coefficients that violate the PH assumption, β(t) is a
function of time.
The structure of a Cox model with time-varying effects is presented in the
equation below:
h(t) = h0(t) exp{β1(t)X1 + β2(t)X2 + · · ·+ βp(t)Xp}. (4.13)
As reviewed in subsection 4.2.9, Schoenfeld residuals are commonly used in
assessing the proportional hazard assumption.
(Grambsch and Therneau, 1994) proved that when β is the regression coef-
ficient from an ordinary Cox model, then,
E(s∗kj) + βj ≈ βj(tk),
where s∗kj is the scaled Schoenfeld residual. Plotting E(s
∗
kj) + βj against
time or any function of time gives a graphical perspective as to whether PH
assumption has been violated or not. The Schoenfeld residual test whether
the effect of a covariate is constant over time by testing for a non-zero slope in
a regression model of the residuals on time. If the test is rejected, it implies
a non-zero slope and hence the hazard is non-proportional (Therneau and
Grambsch, 2000). The shape of the plot gives us an idea of the appropriate
function of time to use for a specific covariate. This is useful when we have
to model non-proportionality by a time-dependent covariate.
In this section, we will discuss three different models that can be used in
modelling covariates with time-varying effects. They are the stratified Cox
model, partitioning the follow-up time or time period and modelling non-
proportionality by a time-dependent covariate.
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4.3.1 The Stratified Cox Model
The stratified Cox model is one of the extensions of the Cox PH model used
for handling covariates that violate the Cox PH assumption. Covariates
are incorporated into the model as stratification factors if the assumption is
violated, whereas covariates that meet the assumption are included in the
model as regressors. The concept behind the model where no interaction is
assumed is that the baseline hazard for different strata are different but the
impact of the covariates are the same across the strata. On the other hand,
when interaction is assumed, the baseline hazard function and the regression
coefficient is dependent on each of the strata.
4.3.1.1 The General Stratified Cox Model
Suppose there are k and p variables that violate the PH assumption and
satisfy the PH assumption respectively. Z1, Z2, · · ·Zk denote the variables
that do not satisfy the assumption whereasX1, X2, · · ·Xp denote the variables
that satisfy the assumption. Then the stratified model formulation is as
follows.
hg(t,X) = h0g(t) exp
[
β1X1 + β2X2 + · · · βpXp
]
, (4.14)
where
g = 1, 2, · · · k∗, strata defined from Z∗, k∗ = the total number of strata in Z∗,
βj = the regression coefficient for the jth X-variables with j = 1, · · · , p and
Z∗ = a variable defined by first identifying the Zi variables not satisfying
the PH assumption. We then categorize each Z and form combinations of
categories of each of the Z’s. Each combination represents a different stratum
making up the variable Z∗.
Despite the effectiveness of this approach in solving the problem of non-
proportionality, there are still some drawbacks. They include:
1. Estimation efficiency is reduced as a result of not being able to esti-
mate the effect of the stratified factors on other variables as they were
not explicitly included in the model. This is the trade-off when using
this approach. Hence, if one is interested in estimating the effect of
a particular variable that happens to violate the PH assumption, this
approach is not the best. An appropriate approach will be to model
the changing effect of the predictor over time directly. This will be
discussed in details later.
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2. It becomes more complicated and messy with continuous and multiple
stratification variables. This is because each covariate that violates the
PH assumption is categorized (including continuous variables and this
is difficult because one needs to have a reference category motivating
the reason behind the way the variable was categorized) and then com-
binations will be made for all the categorization of each of the variables
that violated the PH assumption.
4.3.1.2 Model Estimation
Parameters in this model are estimated by maximizing the partial likelihood
function. The likelihood function in this model is obtained by multiplying
the likelihood functions for each strata. Hence, the partial likelihood function
for the gth stratum is given by
lg(β) =
ng∏
i=1
{
exp(β′x(gj))∑
l∈R(t(gj)) exp(β
′xgl)
}δi
, (4.15)
where,
ng = number of observations in the g
th stratum, x(gi) = is a vector of covari-
ates, R(t(gi)) = subjects at risk in the g
th stratum at time t(gi), t(gi) = the
time the ith subject in the gth stratum was observed and δi = is the event
indicator.
The overall stratified Cox likelihood function is obtained by multiplying the
likelihood from each stratum. It is given as the expression below:
lG(β) =
G∏
g=1
lg(β). (4.16)
4.3.2 Partition the time period
According to Therneau and Grambsch (2000), partitioning the time period is
another way of dealing with covariates that have time-varying effects. Since
the PH assumption was violated over the entire time period, we fit different
Cox models on shorter time periods. Except in cases where there are specific
cut-off time values that may have some clinical implications, the median
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event time is commonly used to partition the time period into sub-intervals.
Everyone still at risk beyond the chosen cut-off time is censored in the first
analysis whereas the individuals considered in the second part of the analysis
are those still at risk after the chosen cut-off time. Results should thus be
interpreted with caution as the interpretation of the models is conditional
on the length of the survival time. It is a necessary to ensure that the PH
assumption is not violated within the short time periods. The setback to
implementing this approach is the reduction in power due to fewer event
times within the intervals.
4.3.3 Model non-proportionality by time-dependent co-
variates
Finally, modelling non-proportionality by time-dependent covariates is an-
other technique proposed by David et al. (1972) to use in handling time
varying effects. A time-dependent variable is created by forming an interac-
tion between the variable that violates the PH assumption and a function of
time t as seen below.
Suppose the regression coefficient for a covariate is a function of time (non-
proportional hazards). We can write
h(t) = h0(t) exp{β(t)X}
= h0(t) exp{βX(t)}, (4.17)
where
X(t) = X × g(t)
and g(t) is a function of time (t). For example, linear or quadratic.
Equation 4.17 shows that a covariate with a time-varying coefficient can
be a expressed as a time-dependent covariate with a constant coefficient.
Common functional forms of time include linear, quadratic and log functions
of time (Bellera et al., 2010). The precision of the final model is dependent
on correctly specifying the function of time. Information on the choice of the
function of time may be governed by knowledge about the behaviour of the
variable over time or the Schoenfeld residuals. The shape of the Schoenfeld
plot of each covariate versus time gives the analyst an idea of the form or
function of time to be assumed. This will be shown in section 5.3.3 where we
allowed the shape of the Schoenfeld residual plot to infer the choice of our
function of time on the Gugulethu data.
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4.4 Time-varying covariates
In all the survival models we have discussed thus far, values of the explanatory
variables incorporated into these models were baseline observations recorded
at the beginning of the study. We have assumed that the values of all co-
variates were determined at the point when follow-up began on each subject
(time zero) and that these values did not change over the period of obser-
vation. However, most survival data are generated as a result of repeated
and multiple observations taken on some explanatory variables of interest.
There may be situations where one or more of the covariates are measured
during the period of follow up and their values change. In these settings,
the case may be that the value of the hazard for the event depends more on
the current values of those covariates than on their values at time zero. An
example is the CD4 cell count and viral load of HIV/AIDS patient in a study
being recorded at every hospital visit. The quality of this data gives a better
and more appropriate indication of the impact of those variables on the haz-
ard of the event of interest (Collett, 2015). Hence, covariates whose values
change over time are commonly called time-varying or time-dependent
covariates.
Time-varying covariates are variables whose values change over time. For
example the CD4 count of an HIV/AIDS patient changes each time it is
measured. However, a time-varying coefficient or effect is one in which the
hazard ratio doesn’t remain constant over time. An example of a time-
varying coefficient or effect is the effect of a treatment which can be strong
immediately after treatment but fades away with time.
4.4.1 Types of Time-varying covariates
Let xi(t) be the covariate vector at time t for the i
th subject and Xk(t) =
{xk(u); 0 ≤ u < t} denote the covariate history up to time t. It is necessary
to consider the different types of time-varying covariates as different methods
are used in handling them. There are two types of time-varying covariates,
endogenous time-varying covariates and exogenous time-varying covariates.
According to Kalbfleisch and Prentice (2011), a time-varying covariate is said
to be exogenous or external if the following condition is satisfied,
P{T ∈ [u, u+ du) |T ≥ u,X(u)} = P{T ∈ [u, u+ du) |T ≥ u,X(t)},(4.18)
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for all u, t such that 0 ≤ u < t. Equivalently, condition 4.18 can be presented
as
P
[
X(t)|X(u), T ≥ u] = P [X(t)|X(u), T = u]. (4.19)
which describes the idea that though their value change over time, the values
are not dependent on whether or when the event occurred. A time-varying
covariate is said to be endogenous or internal if the condition in 4.19 is vio-
lated. Internal or endogenous covariates arise typically when the probability
and timing of the event changes the subsequent values of the covariate.
1. Exogenous covariates: are those whose value at a particular time does
not require subjects to be under direct observation. For example, a
subject’s age. If we follow subjects for a long enough period of time,
their current age may have more of an effect on survival than their
age when the study began. However, once we know a subject’s birth
date, age may be computed at any point in time, regardless of whether
the subject is still under observation. The survival function given an
exogenous covariate can be defined as
Si(t|Xi(t)) = Pr(Ti > t|Xi(t)) (4.20)
= exp
{
−
∫ t
0
hi(s|Xi(s))ds
}
. (4.21)
2. Endogenous covariates: are those whose value is subject-specific, re-
quires the subject to be under periodic observation and requires the
survival of the subject for their existence. For example, a, HIV/ AIDS
study where we are interested in investigating the survival rate of pa-
tients on treatment. Hence, the CD4 count and viral load of the patient
needs to be taken. However, the endpoint of the study is the death of
the patient. Suppose that we have a covariate measured at baseline,
but whose value can change over time. It may be the case that the
hazard depends on a more recent value than on the baseline value. For
values of this covariate to be measured during the follow up period, the
subjects in this study must be under direct observation. The survival
function of an endogenous covariate is defined below as
Si(t|Xi(t)) = Pr(Ti > t|Xi(t)) = 1. (4.22)
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4.5 The Extended Cox model
The Cox PH regression model and its variants that have been fitted thus
far include only baseline covariate measurements. That is, data consist of
only one observation per subject, the covariate measurements are obtained
at study entry and the covariates are treated as time-invariant. The concept
and types of time-varying covariates have been reviewed in sections 4.4 and
4.4.1 respectively. The Cox PH regression model will be an inappropriate
model to use in modelling the survival relationship as it is not designed
to handle time-varying covariates. Therefore, the extended Cox regression
model, which is an extension of the Cox model to handle exogenous time-
dependent covariates using the counting process formulation investigated by
Andersen and Gill (1982), should be used instead.
Figure 4.1: Intuitive representation of the extended Cox model, Rizopoulos
(2012)
Figure 4.1 gives an intuitive idea on how time-varying covariates are han-
dled in the extended Cox model framework. It assumes that the value of
longitudinal marker remains constant between visits.
The extended Cox model (also known as the Andersen-Gill model) is written
as
h(t,X(t)) = h0(t) exp
{ p1∑
i=1
βiXi +
p2∑
j=1
αjXj(t)
}
, (4.23)
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where,
h0(t) = is the baseline hazard function, p1 & p2 = the number of baseline
covariates and number of time-varying covariates, Xi = are time-independent
covariates, Xj(t) = are time-dependent covariates and βi & αj = are the
regression coefficient vectors of the two sets of covariates.s
In equation 4.23, some of the covariates are time-dependent hence the hazard
ratio for any two individuals is also time-dependent and no longer constant.
The regression coefficient vectors (βi and αj) have the same interpretation.
Thus, the regression coefficient in an extended Cox model is interpreted as
the log-hazard ratio of an event at time t that results from one unit increase
in Xi(t) at the same time point.
Estimation of the regression coefficients is by maximizing the partial log
likelihood function below:
l(β) =
n∑
i=1
δi
{ p1∑
i=1
βiXi +
p2∑
j=1
αjXj(t)− log
∑
l∈Ri(t)
exp
( p1∑
i=1
βiXi +
p2∑
j=1
αjXj(t)
)}
,
where
Ri(t) is the risk process with Ri(t) = 1 if individual i is at risk and 0,
otherwise. δi is the event indicator with δi = 0, if survival time of individual
i is censored and 1 otherwise.
4.6 Joint Modeling for Longitudinal and Time-
to-Event Data.
This section presents a summary of the discussion in Rizopoulos (2012) and
Rizopoulos (2018). The extended Cox model is only appropriate for han-
dling exogenous time-varying covariates. It does not handle endogenous
time-varying covariates such as biomarkers appropriately because of the as-
sumption that the values of these covariates only change at visits where
measurements were taken which is unrealistic. Hence, joint modeling is a
more appropriate technique used in assessing the association between an en-
dogenous time-varying covariate and survival. The motivating idea behind
the joint model is to couple the survival model, which is of primary inter-
est with a suitable model for the repeated measurements of the endogenous
covariate that accounts for its special features.
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In this work, the joint model will be used as one of the approaches to han-
dle time-varying covariates with the aim of studying the patient’s survival.
We will begin by specifying the submodels of the joint model, then discuss
how the parameters and random effects are estimated using the maximum
likelihood estimation technique and the Bayes theory respectively. Finally,
extensions of the joint model such as parametrizations (association between
the longitudinal outcome and the hazard of the event) and multivariate joint
models will be considered.
4.6.1 Submodels specification
The joint model is made up of two submodels that are linked together: the
longitudinal and survival submodels. The objective of using the joint model
is to measure the association between the longitudinal marker level and the
risk of an event. The joint model will be achieved in three (3) steps. They
are:
1. The covariate history for each individual is reconstructed from the ob-
served longitudinal response (yi(t)).
yi(t) = mi(t) + i(t)
= xTi (t)β + z
T
i (t)bi + i(t), i(t) ∼ N(0, σ2), (4.24)
where,
xi & β = make up the fixed effect part of the model and zi & bi =
make up the random effect part of the model, bi ∼ N(0, D).
2. Assume that the term mi(t) that denotes the true and unobserved value
of the longitudinal outcome/marker at time t is known. Hence, we can
define the standard relative risk model as
hi(t|Mi(t), wi) = h0(t) exp{γTwi + αmi(t)}, t > 0, (4.25)
where,
Mi(t) = mi(s), o ≤ s < t is the longitudinal history, α = measures
the degree of relationship between the longitudinal marker and risk of
an event, wi = are the baseline covariates and γ = is the vector of the
regression coefficients for the baseline covariates.
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3. In the third step, a joint distribution is described for the two processes
discussed in steps 1 & 2
P (yi, Ti, δi) =
∫
P (yi|bi) {h(Ti|bi)δi S(Ti|bi) p(bi)dbi}, (4.26)
where,
bi = denotes a vector of random effects that explains the ith subject
deviation from the population, p(·) = denotes the density function and
S(·) represents the survival function.
Based on the key assumption of the joint model (conditional independence),
the longitudinal outcome is independent of the survival outcome and the
repeated measurements in the longitudinal outcome are independent of each
other,
p(yi, Ti, δi|bi) = p(yi|bi) p(Ti, δi|bi)
p(yi|bi) =
∏
j
p(yij|bi). (4.27)
The survival function depends on the entire longitudinal marker history.
Si(t|bi) = exp
(
−
∫ t
0
h0(s) exp{γTwi + αmi(s)}ds
)
. (4.28)
In the Cox PH model, it is usual to leave the baseline hazard function unspec-
ified to avoid specifying a wrong distribution for the survival times. In the
joint modeling framework, the standard errors of the parameter that were es-
timated are underestimated if the baseline hazard function is left unspecified.
This limitation is handled by explicitly assuming an underlying distribution
for the baseline hazard function. Distributions such as the Weibull, log-
normal and the Gamma are commonly used. On the other hand, several
approaches that involve non-parametric models with flexible specifications of
the baseline hazard function such as the B-splines, restricted cubic splines,
piecewise-constant model and regression splines have been proposed.
The baseline hazard function for the piecewise-constant model is of the form:
h0(t) =
Q∑
q=1
ξqI(vq − 1 < t ≤ vq), (4.29)
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where 0 = v0 < v1 < · · · < vQ represents the cuts of the time scale, vQ has a
value that is larger than the largest observed time, the value of the hazard
in the interval (vq−1, vq] is represented by ξq.
In the regression model, the logarithm of the baseline hazard function is
expanded into B-spline basis functions for the cubic spline. This is as shown
in the equation below:
log h0(t) = κ0 +
m∑
q=1
κdBd(t, q), (4.30)
where κT = (κ0, κ1, · · · , κm) represent the coefficients of the spline, q is the
degree of the B-splines basis functions B(·) and m = m¨+ q − 1, where m¨ is
the number of interior knots.
In both the piecewise-constant and regression model approach, the more the
number of knots, the better the probability of estimating the baseline hazard
function. However, to avoid over fitting, variability and bias must be brought
into perspective.
4.6.2 Model Estimation
The log-likelihood function of the ith subject is as follows,
log p(Ti, δi, yi; θ) = log
∫
p(Ti, δi, yi, bi; θ)dbi
= log
∫
p(Ti, δi|bi; θt, β)
[∏
j
p{yi(tij)|bi; θy}
]
p(bi; θb)dbi. (4.31)
Equation 4.31 illustrates the dependence of the log likelihood on a time to
event process and a longitudinal process. The density function for the time-
to-event process is as follows,
p(Ti, δi|bi; θt, β) = hi(Ti|Mi(Ti); θt, β)δiSi(Ti| Mi(Ti); θt, β)
=
[
h0(Ti) exp{γTwi + αmi(Ti)}
]δi
× exp
(
−
∫ Ti
0
h0(s) exp{γTwi + αmi(s)}ds
)
.(4.32)
where the baseline hazard function h0(·) could assume underlying distribution
of time as discussed above. To estimate the parameter θ, the log-likelihood
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function in 4.31 is maximized using some numerical optimization algorithms
such as the Expectation - Maximization (EM) algorithm or the Newton-
Raphson algorithm amongst others.
The joint density function for longitudinal responses with random effects is
as shown below:
p(yi|bi; θ)p(bi; θ) =
∏
j
p{yi(tij)|bi; θy}p(bi; θb)
= (2piσ2)ni/2 exp{||yi −Xiβ − Zibi||2/2σ2}
× (2pi)qb/2 det(D)−1/2 exp(−bTi D−1bi/2). (4.33)
Estimation of the random effects as proposed by Rizopoulos (2012) is carried
out using the Bayesian methods. Hence, estimates for the random effects are
based on the posterior distribution. With a prior distribution in of the form
p(bi; θ) and a conditional likelihood function p(bi|Yi, δi, yi, θ)p(yi|bi; θ),.
p(bi|Yi, δi, yi, θ) = p(Yi, δi|bi, θ)p(yi|bi; θ)p(bi; θ)
p(Yi, δi, yi; θ)
∝ p(Yi, δi|bi, θ)p(yi|bi; θ)p(bi; θ). (4.34)
Since equation 4.34 does not have closed solution, it is solved numerically
and the measures of location used are the mean or the mode with their forms
presented below:
{
b¯i
∫
bip(bi|Yi, δi, yi; θ)and
bˆi arg maxb{log p(bi|Yi, δi, yi; θ)}.
4.6.3 Extensions of the Joint Model
In this section, we will consider extensions of the standard joint model we
have considered before. These extensions include the parametrization of the
association structure between the longitudinal and event outcomes and fitting
joint models for multiple longitudinal responses.
43
4.6. JOINT MODELING FOR LONGITUDINAL AND
TIME-TO-EVENT DATA.
4.6.4 Parametrization
In the standard joint model, we assumed that the risk of an event of interest
at time t, depends on the true level of the longitudinal marker at that time.
The parameter α measures the degree of association or dependency. This as-
sumption may be violated. In a situation whereby the assumption is invalid,
the results obtained will be inappropriate and lead to incorrect medical con-
clusions. In this section, different assumptions are made on the association
structure between the risk of an event and the longitudinal outcome. They
include the lagged effect parametrization, the interaction effect parametriza-
tion, the cumulative effect parametrization, the weighted cumulative effect
parametrization and the time-dependent slopes parametrization.
The risk of an event at a particular time in a lagged effect parametrization,
is assumed to be associated with the level of the longitudinal outcome at a
preceding time point.
hi(t) = h0(t) exp[γ
Twi + αmi{max(t− c, 0)}] (4.35)
where c is the time lag one is interested in.
The interaction effect parametrization allows the effect of the risk of an event
on the longitudinal outcome to differ in all subgroups of the intended popu-
lation. This is done by introducing an interaction term as this will accommo-
date the different measures of associations in the subgroups. The formulation
of this type of parametrization is as shown below:
hi(t) = h0(t) exp[γ
Twi1 + α
T{wi2 ×mi(t)}] (4.36)
where,
wi1 = denotes a vector that includes the direct effects of baseline covariate to
the risk for an event, wi2 = contains covariates that are allowed to interact
with mi(t), thereby allowing different associations for different subgroups of
the data.
The time-dependent slopes parametrization allows the risk of an event to
depend on other features of the longitudinal trajectory such as the slope.
Hence, the formulation below is when we assume that the risk of an event
depends on the current value and slope of the longitudinal trajectory.
hi(t) = h0(t) exp{γTwi + α1mi(t) + α1m′i(t)} (4.37)
where
m
′
i(t) =
d
dt
mi(t) =
d
dt
{xTi (t)β + zTi (t)bi}
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α1 measures the degree of the association between the risk of an event at
time t and the current longitudinal outcome at the same time. On the other
hand, α2 measures the degree of the association between the risk of an event
at time t and the slope of the longitudinal outcome at the same time provided
mi(t) is constant.
The cumulative effect parametrization is more or less an extension of the
time-dependent slopes parametrization. In the time-dependent parametriza-
tion, the risk of an event at time t is assumed to depend on other features
of the longitudinal outcome either at the same time or lagged time. In ad-
dition, this is assumed for a single time point. However, in the cumulative
effect parametrization, the risk of an event at time t is assumed to depend
on the cumulative trajectory of the longitudinal outcome.
hi(t) = h0(t) exp{γTwi + α
∫ t
0
mi(s)ds} (4.38)
The strength of the association between the risk of an event at time point t
and the cumulative longitudinal trajectory up to the same time t is measured
by α.
The cumulative effect parametrization assumes the same weights for all the
longitudinal values whether they were observed currently or in the past. How-
ever, in the weighted cumulative effect parametrization, weight functions that
places different weights at different time points are chosen. The formulation
is as shown below:
hi(t) = h0(t) exp{γTwi + α
∫ t
0
$(t− s)mi(s)ds} (4.39)
where $(·) denotes the weight function. A desirable property of $(·) would
be to place smaller weights in points further in the past.
4.6.5 Joint models for multiple longitudinal responses
All along we have fitted joint models that have only one longitudinal outcome.
However, there are situations were multiple longitudinal outcomes/biomarkers
are useful in predicting the hazard of an event. For example, in the Gugulethu
HIV/AIDS data, lCD4 and Tx are longitudinal outcomes essential in predict-
ing the risk of death.
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The multivariate generalized linear mixed model is used to accommodate the
different longitudinal outcomes in a joint model framework with the condi-
tional distribution of kth outcome given a vector of random effects bki being
a member of the exponential family, with linear predictors given by
gk[E{yki(t)|bki}] = ηki(t) = xTkiβk + zTkibki, bTki ∼MVN(0, D)(4.40)
where,
gk = represents the one-on-one monotone link function, yki = is the kth
longitudinal outcome for the ith individual at time t, xTki & z
T
ki = the vector
of the fixed and random effects respectively, D = the variance/ covariance
matrix of the random effects.
The hazard model for the multiple longitudinal outcome is given as
hi(t) = h0(t) exp[γ
Twi +
K∑
k=1
Lk∑
l=1
fkl{Hki(t), wi(t), bki, αkl]
= h0(t) exp{γTwi +
K∑
k=1
αkηki(t)} (4.41)
where
Hki(t) = {ηki(s), 0 ≤ s < t} is the history of the longitudinal process up to t,
h0(t) = is the baseline hazard function modeled using the B-splines,
wi = denotes the vector of covariates with ts regression coefficient γ.
Just like in the standard joint model where different parametrization struc-
ture for the association parameter were assumed, the same is applicable in
joint models for multiple longitudinal responses.
f{Hi(t), wi(t), bi, α} = αηi(t), (4.42)
f{Hi(t), wi(t), bi, α} = α1ηi(t) + α2η′i(t) with η
′
i(t) =
dηi(t)
dt
, (4.43)
f{Hi(t), wi(t), bi, α} = α
∫ t
0
ηi(s)ds (4.44)
Equation 4.42 assumes that the risk of an event at a particular time t is
associated with the longitudinal outcome at the same time point. Equations
4.43 and 4.44 assume that the risk of an event at a particular time t is
associated with the slope of the longitudinal outcome at the same time point
or the cumulative trajectory up to time t respectively.
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4.6.5.1 Model Estimation
The parameters in the multivariate joint model are estimated by maximis-
ing the log-likelihood function in equation 4.45 below using the Bayesian
approach.
The posterior distribution of the model parameters given the observed data is
derived under the assumptions that given the random effects, the longitudinal
outcomes are independent from the event times, the multiple longitudinal
outcomes are independent of each other, and the longitudinal responses of
each subject in each outcome are independent. Under these assumptions the
posterior distribution is analogous to:
p(θ, b) ∝
n∏
i=1
K∏
k=1
nkl∏
j=1
p(ykij|bki, θ)p(Ti, TUi , δi|bki, θ)p(bki|θ)p(θ) (4.45)
where,
θ = denotes the full parameter vector, p(θ, b) = the posterior distribution of
the model given the random effects, p(ykij|bki, θ) = the density for the lon-
gitudinal part and p(Ti, T
U
i , δi|bki) = the density distribution of the survival
part.
The longitudinal part of the model is
p(ykij|bki, θ) = exp{[ykijψkij(bki)− ck{ψkij(bki)}]/ak(ϕ)− dk(ykijϕ)} (4.46)
with ψkij(bki) and ϕ denoting the natural and dispersion parameters in the
exponential family respectively, ck(·), ak(·) and dk(·) are known functions
specifying the member of the exponential family.
For the survival part accordingly we have
p(Ti, T
U
i , δi|bki, θ) = {hi(Ti|Hi(Ti), wi(Ti))}I(δi=1) exp{−
∫ Tt
0
hi(s|Hi(s), wi(s))ds}
× {1− exp{−
∫ Tt
0
hi(s|Hi(s), wi(s))ds}}I(δi=2)
× {exp{−
∫ Tt
0
hi(s|Hi(s), wi(s))ds}
− exp{−
∫ Tt
0
hi(s|Hi(s), wi(s))ds}}I(δi=3) (4.47)
where I(·) is the indicator function, TUi , δi = 2 and δi = 3 are used when the
data is interval censored.
47 4.7. AALEN’S ADDITIVE HAZARD REGRESSION MODELS
4.7 Aalen’s additive hazard regression mod-
els
The following section comprises of the Aalen’s additive hazard regression
models and the semi-parametric additive hazards model are summaries from
Martinussen and Scheike (2007). The multiplicative regression models such
as the Cox PH model have been our focus until this point. In the multiplica-
tive regression models specifically the Cox PH model, the hazard function
is associated with the multiplicative effect of the covariates on the baseline
hazard (, 2008), and these effects are expected to remain constant over time.
However, there are situations whereby the additive effect of the covariates is
what is of interest. These are referred to as additive models. It is based on
the assumption that the effect of covariates on a subject accumulates over
time in its action to either cause or prevent the event. Unlike in multiplica-
tive regression models were instantaneous effect of the event of interest is
obtained, in additive regression models, the effects are allowed to be realised
some time after the change in the covariate has occurred.
In 1980, Aalen introduced the Aalen’s additive hazard regression model. This
model was developed further in 1989 and 1993 (Hosmer et al., 2011). It is
a flexible non-parametric (that is no distributional assumption is made for
the hazard rate) model as it accommodates the inclusion of time-varying
effects/covariates.
In Aalen’s additive model with p-covariates, x(t) = (x1(t), · · · , xp(t))T , the
conditional hazard function at time t is of the form
h(t,x, β(t)) = Y (t)xT (t)β(t) (4.48)
= Y (t)(x1(t)β1(t) + · · ·+ xp(t)βp(t)),
where,
β(t) = (β1(t), · · · , βp(t))T is the vector of regression coefficients, Y (t) = is the
risk indicator and xT (t) = (x1(t), · · · , xp(t))T is the vector of time-varying
covariates.
The regression coefficient in 4.48 is a function of time. Hence, it is time
dependent which implies that the effect of the covariates may change with
time.
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The cumulative hazard function obtained from the hazard function in 4.48 is
H(t,x,B(t)) =
∫ t
0
h(u,x(u),β(u))du
=
p∑
k=0
xk(u)
∫ t
0
βk(u)du
=
p∑
k=0
xk(t)Bk(t) (4.49)
The kth covariate has the cumulative regression coefficient, Bk(t). Aalen
noted that the cumulative regression coefficients are easier to estimate com-
pared to the regression coefficient. The former is known to converge at a
faster rate compared to the latter.
The cumulative regression functions are plotted against time for each covari-
ate. This plot describes how covariates influence survival over time. If the
estimated cumulative regression coefficient is constant over time, the plot
looks like a straight line through the origin with slope equal to the coeffi-
cient’s value. This implies that the effect of the covariate does not vary with
time. However, if there are deviations from the straight line at any time inter-
val shows an evidence of the covariate having a time-varying effect (Hosmer
et al., 2011). In addition, the slope of plots are intuitive as this indicates
whether a specific covariate has time-varying effect or not. For plots with
positive slopes, we conclude that increasing the covariate increases hazard
whereas negative slopes occur when increasing the covariate decreases haz-
ard during periods (BAS¸AR, 2017). Examples of these plots will be shown
in section 5.8.
4.7.1 Model Estimation
The cumulative regression coefficient for Aalen’s additive model can be esti-
mated using several techniques such as the non-parametric approach with a
uniform asymptotic and using the ordinary least-squares. Aalen (1980) in-
troduced estimating the cumulative regression coefficient using the ordinary
least-squares (Martinussen and Scheike, 2007).
The Aalen additive model has the intensity for the counting process N(t)
conditioned on the covariates as given in equation 4.48. Λ(t) =
∫ t
0
λ(s)ds
is the n-dimensional cumulative intensity with M(t) = N(t) − Λ(t) as the
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n-dimensional martingale.
dNi(t) = h(t)dt+ dM(t)
= X(t)β(t)dt+ dM(t) (4.50)
Equation 4.50 has the form of the ordinary linear regression model where
dNi(t) is the response, X(t) the covariates , β(t) is the parameter vector to
be estimated and dM(t) denotes the random error term.
β(t) can be rewritten as dB(t) and can be estimated using the multiple linear
regression method. The ordinary least squares estimator gives
dBˆ(t) = (X(t)TX(t))−1X(t)TdN(t). (4.51)
When X(t) is a full rank, J(t), a Jacobian is introduced as an indicator with
the value of 1 in the existence of the inverse and 0 otherwise. The least
squares generalised inverse is given as
X−(t) = (X(t)TX(t))−1X(t)T , (4.52)
which satisfies the relation X−(t)X(t) = J(t)Ip where Ip is an identity ma-
trix. Substituting the values of X−(t) in equation 4.52 into 4.51 we have an
estimator
dBˆ(t) = X−(t)dN(t) (4.53)
Equation 4.53 can be re-written in the integral form as
Bˆ(t) =
∫ t
0
X−(s)dN(s) (4.54)
4.7.2 Inference for Aalen’s additive hazard regression
models
This section presents approaches for conducting inference for the additive
hazards model. The hypothesis can be stated in terms of either the regression
coefficients (β) or the cumulative regression coefficients (B). Two hypothesis
will be considered:
H01 : Bp(t) ≡ 0 vs HA1 : Bp(t) 6≡ 0 (4.55)
H02 : Bp(t) ≡ γt vs HA2 : Bp(t) 6≡ γt (4.56)
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Hypothesis 4.55 tests whether one of the components differs significantly
from zero and hypothesis 4.56 tests whether at least one of the components
has constant effect with time. Hypothesis 4.55 can be evaluated using either
the Hall - Wellner confidence band approach obtained by the resampling
technique or the simulation based confidence band and observing whether or
not the zero function is contained within the band. The effect of a variable
is significant if the zero function of the confidence band is contained outside
the bands. However, this approach can’t evaluate hypothesis 4.56 because
the uncertainity of not knowing γ is not reflected by looking at the Hall-
Wellner confidence band. Hypothesis 4.56 can be tested using either the
Kolmogorov-Smirnov test or the Crame´r-von Mises test (Martinussen and
Scheike, 2007).
Several test statistics can be used in analysing the hypothesis in equation
4.55. Some of them include the Hall - Wellner confidence band approach
presented in equation 4.61 below, the maximal deviation test statistics
T˜1S = sup
t∈[0,τ ]
|Bˆp(t)|, (4.57)
or revised version of the maximal deviation test statistics that considers the
variability of Bˆp(t)
sup
s,t∈[0,τ ]
|Bˆp(s)− Bˆp(t)|. (4.58)
The Hall-Wellner confidence band is based on a Gaussian Martingale, Up(t),
with covariance function Φpp(t),
Up(t)
Φpp(τ)
1
2
Φpp(τ) + Φpp(t)
, (4.59)
which has the same distribution as
B0
Φpp(t)
1
2
Φpp(τ) + Φpp(t)
. (4.60)
where B0 is the Brownian bridge. Thus, the Hall-Wellner confidence band is
given by
Bˆp(t)± n 1ndαΦpp(t) 12
(
1 +
Φpp(t)
Φpp(τ)
)
, t ∈ [0, τ ] (4.61)
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where the pth diagonal element of Φ is Φpp and dα is the upper α- quantile
of supt∈[0,1/2] |B0(t)|.
After the confidence band has been calculated, examining if the zero function
is within the band or not is used as a criteria in testing the hypothesis
presented in equation 4.55. This approach cannot be used in evaluating
the hypothesis that the regression coefficients are time-invariant because the
uncertainties and variabilities surrounding γ is not known.
Testing the hypothesis presented in equation 4.56, the following test statistics
are considered,
T2S = n
1
2 sup
t∈[0,τ ]
|Bˆp(t)− Bˆp(τ) t
τ
|, (4.62)
and
T21 = n
∫ τ
0
(
Bˆp(t)− Bˆp(τ) t
τ
)2
. (4.63)
Based on the results obtained from from equations 4.62 and 4.63, some test
such as the Kolmogorov-Smirnov test or the Crame´r-von Mises test are con-
structed. They are used in testing the hypothesis presented in equation 4.56.
The Kolmogorov-Smirnov test rejects at level α if
sup
t≤τ1
|Vˆ ∗p (t, τ2)/(nΦˆpp)
1
2 | ≥ fα (4.64)
where fα = the (1−α)-quantile in the distribution of sup0≤x≤1 |B(x)| with B
the standard Brownian motion and Φpp = Φpp(τ1). V
∗
p (t) = n
1
2 Bˆp(t)−Bˆp(τ) tτ .
fα is assigned specific values.
The Crame´r-von Mises test rejects at level α if∫ τ1
0
(
Vˆ ∗p (t, τ2)/(nΦˆpp)
1/2
1 + Γˆ(t)
)2
d
(
Γˆ(t)
1 + Γˆ(t)
)
≥ eα (4.65)
where eα = the (1−α)-quantile in the distribution of
∫ 1/2
0
B0(u)2du with B0
the standard Brownian bridge and Γˆ(t) = ˆΦpp(t)/Φpp.
fα and eα in the Kolmogorov-Smirnov and Crame´r-von Mises tests are as-
signed specific values.
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4.8 The Semi-parametric additive hazards
model
The semi-parametric additive hazard model is an extension of the additive
Aalen model. Several researchers have proposed different forms of the semi-
parametric additive hazard model. Lin and Ying (1994) proposed a model
whereby the hazard function is positive and the regression coefficients are
time-invariant. Unlike the additive Aalen model where all its regression co-
efficients are time-varying, the semi-parametric additive hazards model struc-
ture proposed by McKeague and Sasieni (1994) combines the time-varying
coefficients of the Aalen model with time-invariant coefficients. We will make
use of the semi-parametric structure proposed by McKeague and Sasieni.
The semi-parametric additive hazards model is applicable when one is inter-
ested in investigating the nature of covariates effect, as to whether all the
regression coefficients are time dependent. In addition, this approach can
be used in reducing the degrees of freedom in the case of limited amount of
data, thus ensuring precise results. This model verifies if the regression coef-
ficients with time-varying effects are in fact significantly varying with time.
The effect of each covariates should be carefully studied to investigate if they
are time-varying before reducing to the semi-parametric model. An effective
and efficient approach to handle this is to start with a model that allows
the effect of all variables to be time-varying. Further investigation should be
made to ascertain if some of the effects are well described by constants and
then successively simplifying the model as appropriate. The structure of the
semi-parametric additive hazard model is presented in equation 4.66 below.
λ(t) = Y (t)(xT (t)β(t) + zT (t)γ), (4.66)
where,
λ(t) is the hazard rate, x(t) & z(t) are time-varying covariates, Y (t) is the
at risk indicator, that is the variable that signifies if an individual is at risk
or not, β(t) is a vector of time-varying regression coefficient and γ is a vector
of time-invariant coefficient.
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4.8.1 Model estimation
Let X(t) = (X1(t), · · · , Xn(t))T denote the covariates with time-varying co-
efficients and Z(t) = (Z1(t), · · · , Zn(t))T denote the covariates whose effects
are time-invariant. The martingale decomposition of the counting process is
given as
dNi(t) = λ(t)dt+ dM(t),
= X(t)β(t)dt+ Z(t)γdt+ dM(t). (4.67)
dB(t) and γ will be estimated using the following least squares equations.
XT (t)(dN(t)− λ(t)dt) = 0, (4.68)∫
ZT (t)(dN(t)− λ(t)dt) = 0, (4.69)
Solving equation 4.69 for the regression coefficient of the covariates with
time-invariant effects, we have
dBˆ(t) = X−(t){dN(t)− Z(t)γdt}. (4.70)
Substituting the results from equation 4.70 into equation 4.69 and solving
for γ as well as integrating gives
γˆ =
{∫ T
0
ZT (t)H(t)Z(t)dt
}−1 ∫ T
0
ZT (t)H(t)dN(t) (4.71)
where H(t) = (I −X(t)X−(t)). Using equation 4.70 with γˆ gives
Bˆ(t) =
∫ t
0
X−(s)(dN(s)− Z(s)γˆds). (4.72)
Estimation of the variance of ˆβ(t) in the Aalen additive model and ˆβ(t) and
γ in the semi-parametric model is based on the regularity conditions being
satisfied, the root-n difference between the estimator and true cumulative
regression function converges in distribution to a Gaussian martingale. The
results obtained follows some functional forms of the strong laws of large
numbers. The variances can be estimated using various approaches such
as the optimal variation processes and the independent and identically dis-
tributed (iid) martingale decomposition. Details on the estimation of the
variance terms for ˆβ(t) in the Aalen additive model and ˆβ(t) and γ in the
semi-parametric model is found in Martinussen and Scheike (2007).
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4.8.2 Inference for the semi-parametric additive haz-
ard model
In this section, approaches for conducting inference in the semi-parametric
additive hazards model will be presented. Two hypothesis will be considered:
H01 : Bp(t) ≡ 0 vs HA1 : Bp(t) 6≡ 0 (4.73)
H02 : Bp(t) ≡ γq+1t vs HA2 : Bp(t) 6≡ γq+1t (4.74)
It should be noted that the effects of the z-covariates in 4.66 are time invari-
ant. Just like in the inference for the Aalen additive hazard model, hypothesis
4.73 can be evaluated using the Hall- Wellner confidence band approach ob-
tained by either the resampling technique or the Khmaladze transformation.
The procedure that has been constructed to test hypothesis 4.74 is the ob-
served test-process and this shows the nature of deviation from the null
hypothesis and where it occurs or the modified observed test-process (this
takes the variance into account).
Chapter 5
Data Analysis and result
interpretation
5.1 Introduction
Chapter 4 covered the methodology for the analysis of time-to-event data,
with specific focus on methods for dealing with time-varying effects and for
incorporating time-varying covariates. This chapter represent an application
and assessment of these methods using the data from the HIV cohort.
5.2 The Cox Regression model
The analysis is based on data for 9,152 individuals followed up for up to 65
months. 818 of them experienced the event of interest, which is death. The
Cox model is used to determine the association between the relative hazard
of the death and baseline covariates. The structure of the model fitted is
shown below:
log
{
hi(t)
h0(t)
}
= β1 Agei + β2 Malei + β3 Stage2i + β4 Stage3i + β5 Stage4i
+ β6 lCD40i (5.1)
The output from the Cox proportional model is presented below. All the
covariates (age, gender, Stage2, Stage3, Stage4) have statistically sig-
nificant associations with the relative risk of death.
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Table 5.1: Results of the Cox regression model.
Covariate Coef. HR SE lower .95 upper .95 p-value
Age 0.03 1.03 0.00 1.022 1.036 <0.001
Male 0.18 1.19 0.07 1.036 1.375 0.014
Stage2 0.38 1.46 0.19 1.013 2.113 0.042
Stage3 1.29 3.62 0.15 2.718 4.826 <0.001
Stage4 1.75 5.75 0.15 4.263 7.751 <0.001
lCD40 -1.18 0.31 0.06 0.275 0.346 <0.001
Table 5.1 presents the result of the Cox regression model. The estimated
regression coefficients are given in the second column of Table 5.1 and the
estimated relative hazards which is the exponentiated coefficients or hazard
ratio is in the third column. It is interpreted as the multiplicative effects
on the hazard. The covariates Stage2, Stage3, Stage4 are binary with the
value 1 for an individual whose HIV/AIDS status is in any of the respective
Stages. Gender, is also a binary variable with the value 1 when the subject
is male and 0 when female.
Holding other covariates constant, the estimated relative hazard in patients
whose HIV/AIDS status is Stage4 is 5.75 times that of patients in Stage1.
In addition, keeping the value of the other covariates fixed, Stage3 has
3.62 times an estimated relative hazard compared to Stage1. Furthermore,
Stage2 has 1.46 times an estimated relative hazard compared to Stage1
when every other covariate is kept constant. From the results, we observed a
progressive increase in the relative hazard as a patients status changes from
Stage1 to other Stages. This implies that the higher the stage in which an
HIV/AIDS patient is in, the higher the relative hazard.
CD4 is fitted using a log transformation due to its skewness. It has a negative
estimated coefficient. CD4 molecules are used to measure normal immunity
and HIV infection. Each 1 unit increase in the log of the baseline CD4 is
associated with about 69% decrease in a patient’s relative hazard of death.
Finally, holding other covariates constant, an additional year in age increases
the relative hazard of death by a factor of 1.03 on average, that is by, 3%.
5.2.1 Model Checking
In section 4.2.4 we reviewed several model diagnostics that have been pro-
posed to be used in verifying the adequacy of fitted Cox regression models. In
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this section, we will be applying the following model diagnostics: Schoenfeld
residuals, martingale residuals, Cox-Snell residuals, deviance residuals and
dfbeta residuals to investigate the model fitted to the Gugulethu HIV/AIDS
dataset.
5.2.1.1 Cox-Snell Residuals
The Cox-Snell residual is used in examining the overall fit of the Cox model.
A straight line through the origin with a slope of 1 is expected if the Cox
model provides a good fit of the data. Figure 5.1 below presents a plot of
the Cox-Snell residuals. The line shows some deviation from the 45-degree
reference line thus indicating that the Cox model may not provide a good fit
for the model.
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Figure 5.1: Cox-Snell residual plot
The limitation of the Cox-Snell residual is that it is not specific on which
part of the model is not fitting properly. Hence, we will consider other model
diagnostics to evaluate the goodness of fit for specific parts of the model.
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5.2.1.2 Martingale Residuals
The martingale residual as reviewed in section 4.2.6 is used in examining the
importance of certain variables in the model and in verifying if the functional
forms of the covariates are appropriate after other covariates have been in-
cluded in the model or if there is a need for transformation. Hence, we plot
the martingale residuals against the continuous covariates, if there are pat-
terns in the plots, it suggests that the functional form of the variable is not
appropriate.
There are two continuous variables amongst the variables of interest in the
Gugulethu HIV/AIDS dataset. They are Age and lCD40. To investigate if
those variables are important in the model, we fit a model excluding each
variable one at a time. Figure 5.2 below shows the plot of the residuals of
these model versus the excluded variables.
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Figure 5.2: Martingale residual plots for Age and lCD40 when not included in
the model
The plot of residual versus age shows a positively linear relationship whereas
the plot of residual versus the logged baseline CD4 shows a linearly decreasing
relationship.
Furthermore, both variables were included into the model to observe their
impact and ascertain that the functional form of the variables are suitable.
This is shown in Figure 5.3 below.
Both plots in Figure 5.3 provide a good fit. Age being brought into the model
in a linear form provides a good fit as the loess line wiggles around zero and
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Figure 5.3: Martingale residual plots for Age and lCD40 when they are included
in the model.
there seems to be no trend. The plot of residuals versus the logged baseline
CD4 shows some deviation from the horizontal line indicating a possible non-
linear association.
5.2.1.3 Deviance Residuals
Recall from section 4.2.7 that the deviance residual is a scaled martingale
residual that has a considerably symmetrical distribution about zero. Due
to this, outlying observations are considered to values beyond of the range
of ±2, (n.d.) and Braun (2011).
The aim is to determine if there are outlying observations in the Cox model
with all the covariates in it. The linear predictor estimates and the deviance
residuals are obtained from the model. A plot of deviance residuals versus
the linear predictors for the event of interest (death) is presented in Figure
5.4 below. 5.4 shows the characteristic of two cluster of residuals for subjects
who did experience the event and those who were censored (residuals < 0).
A large number of residual were greater than +2 among the subjects who
experienced the event of interest, indicating that the Cox PH model did not
fit the data well.
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Figure 5.4: Deviance residual plot for the Cox PH model
5.2.1.4 DfBeta Residuals
Just as reviewed in section 4.2.8, Figure 5.5 represents the index plot of
the dfbeta for the Cox PH regression model. Comparing the magnitudes
of estimated regression coefficients upon deleting each observation in turn
with that of the estimated regression coefficients from the whole dataset and
dividing them by their standard errors suggests that none of the observations
is influential since none of the dfbeta values exceeded ±0.02. This value was
based on the guideline in 4.10 where n = 9152. However, clusters or isolated
points of potential influence are visible in figure 5.5, especially for the Stage
dummy variables. They are in fact the subjects who were in each specific
stage.
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Figure 5.5: Index plots of dfbeta for the Cox PH regression model
5.2.1.5 Schoenfeld Residuals
The Cox proportional hazards model assumes that the effect of covariates
on the relative hazard of the event stays constant over time. The Schoenfeld
residual is used to test the proportional hazard assumption in Cox model.
For each covariate, scaled Schoenfeld residuals were plotted over time, and
tests for a zero slope were performed. Table 5.2 below reports the corre-
sponding p-value for each covariate, as well as the p-value associated with
a global test of non-proportionality. The global test suggested strong evi-
dence of non-proportionality (p < 0.001). The covariates Age and lCD40
with (p-values = 0.033 and <0.001) respectively contributed to the overall
non-proportionality of the model. These numerical findings suggest a non
constant hazard ratio for these variables. On the other hand, the covariates
Male, Stage2, Stage3 and Stage4 were found to follow the proportional
hazards assumption with p-values of 0.712, 0.389, 0.972 and 0.480 re-
spectively.
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Table 5.2: Test for non-proportionality based on the scaled Schoenfeld residuals
for the Cox model.
Covariate rho chisq p-value
Age 0.074 4.556 0.033
Male 0.013 0.136 0.712
Stage2 0.030 0.743 0.389
Stage3 0.001 0.001 0.972
Stage4 -0.024 0.498 0.480
lCD40 0.238 37.498 <0.001
GLOBAL NA 55.764 <0.001
Residuals help in visualizing the log hazard ratio β over time for each co-
variate see Figure 5.6 below. The PH assumption is violated if the plot of
Schoenfeld residuals against time shows a non-random pattern and if the
plotted curves are not roughly constant with time. The graphical approach
confirms the results in Table 5.2. The plot of the log hazard ratio for Gender,
Stage2, Stage3 and Stage4 confirms that the effect on the hazard of death
is constant throughout the follow-up time. The residuals of the covariates
that violate the PH assumption (Age and lCD40) seem to follow some pat-
tern and the curves aren’t approximately constant over time. With respect
to the baseline Age variable, the plot suggests a strong effect over the first
four months which tends to diminish over time.
At the early to mid stages, from zero to 30 months, the effect of the logged
baseline CD4 count is very negative on the hazard of death, that is, lCD40 is
highly protective. This effect decreases with time and by 60 months it seems
that lCD40 stops being protective from death (zero is the point of equivalence
in the log hazard scale). The estimate of lCD40 having a 69% decreased
effect on the relative hazard of death suggested at the end of section 5.2 is
misleading because if one regarded this as true, they would under-estimate
the strong protective effect of treatment at the early stages and over-estimate
the effect at the later stages. Without the plot of the effects, one would not
only be missing out on valuable information of the variation of the effect over
time, but may also reach incorrect conclusions or recommendations.
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Figure 5.6: Schoenfeld residual plots with 95% pointwise confidence intervals for
all the covariates
65 5.3. TIME VARYING EFFECTS/ COEFFICIENTS
5.3 Time Varying Effects/ Coefficients
In 4.4, distinctions were made between time-varying coefficients and time-
varying covariates. Subsequent sections will illustrate various approaches
that have been proposed on how to handle time-varying coefficients since the
basic assumption on which the Cox proportional hazard model is based on
was violated in the in the HIV/AIDS data.
5.3.1 The stratified Cox model
As mentioned previously in section 4.3.1.1, the stratified Cox model is one of
the methods used in dealing with covariates that have time-varying effects.
In the Gugulethu HIV/AIDS data we analysed in section 5.2, two covariates
were found not to have constant hazard ratios, Age and lCD40. However,
both variables are continuous. To fit the stratified Cox model, the variables
that violate the PH assumption ought to be categorical. Therefore, we split
Age into 4 categories (0 − 5 years, 6 − 19 years, 20 − 39 years and 40 −
85 years) and lCD40 was split into 3 categories (< log(200), log(200 −
499), ≥ log(500)). The criteria on which the covariates were split can be
found in WHO et al. (2005). After both variables have been categorised,
we formed (4 × 3 = 12) Age group-by- lCD40 status combinations. This is
presented in the table below.
Table 5.3: Age group-by-lCD40 status combination.
Age
lCD40
0-5 6-19 20-39 40-85
< log(200) 1 (16) 2 (96) 3 (3426) 4 (1238)
log(200− 499) 5 (31) 6 (153) 7 (2618) 8 (92)
≥ log(500) 9 (137) 10 (78) 11 (459) 12 (808)
These 12 combinations represent the different categories of a single new vari-
able that we stratify on in the stratified Cox model. The values in brackets
are the number of subjects in each stratum. In this model we assumed no
strata by covariate interaction. Below is the structure of the model that was
fitted:
hgi(t) = h0gi exp
{
β1 Malei + β2 Stage2i + β3 Stage3i + β4 Stage4i
}
, (5.2)
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where g = 1, · · · 12.
Table 5.4 below presents the results of the stratified Cox regression model.
Table 5.4: Results of the stratified Cox regression model.
Covariate Coef. HR SE p-value
Male 0.241 1.272 0.071 0.001
Stage2 0.393 1.481 0.187 0.036
Stage3 1.369 3.932 0.145 <0.001
Stage4 1.960 7.096 0.149 <0.001
Despite the many advantages of stratification; simple to implement and han-
dles the issue of non-proportionality, the major drawbacks of stratification of
not being able to obtain estimates for the effects of variables used in stratifi-
cation, diminished precision and power of the estimated regression makes is
less attractive. Hence, if we are interested in knowing the effect of Age and
lCD40 on the event of interest (death), this approach will not be appropriate
as we cannot say anything about them because they weren’t obtained. On
the other hand, if we are not interested in the variables that were used as
the stratifying variables, we will interpret the results in Table 5.4 as having
adjusted for other covariates including the stratifying covariates, the haz-
ard ratio for the effect of Males is given by 1.27. This implies that Males
have 1.27 times the risk of death compared to females. In addition, Stage2,
Stage3 and Stage4 have 1.48, 3.93 and 7.10 times the hazard of death
respectively compared to Stage1. We see that while the magnitude of the
effects of these variables have changed compared to the Cox PH model pre-
sentation in Table 5.1, the general associations/trends are the same.
Another limitation of the model fitted with no strata by covariate interaction
assumption is that it is probably not the case for the HIV/AIDS data set as
Age and lCD40 would most likely affect other variables.
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Figure 5.7: Cumulative baseline hazard function for the stratified model.
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Figure 5.7 below presents the cumulative baseline hazards plots for the
12 strata representing the combination of three lCD40 categories namely
< log(200), < log(200 − 499) and ≥ log(500) and four Age categories: 0-5,
6-19, 20-39 and 40-85. Strata 1 are individuals in the 0-5 years age cate-
gory and have a lCD40 count of less than log(200). Strata 2 are individuals
in the 0-5 years age category and have a lCD40 count between log(200−499).
Strata 3 are individuals in the 0-5 years age category and have a lCD40 count
greater than or equal to log(500).
Strata 4 are individuals in the 6-19 years age category and have a lCD40
count of less than log(200). Strata 5 are individuals in the 6-19 years age
category and have a lCD40 count between log(200− 499). Strata 6 are indi-
viduals in the 6-19 years age category and have a lCD40 count greater than
or equal to log(500).
Strata 7 are individuals in the 20-39 years age category and have a lCD40
count of less than log(200). Strata 8 are individuals in the 20-39 years
age category and have a lCD40 count between log(200 − 499). Strata 9 are
individuals in the 20-39 years age category and have a lCD40 count greater
than or equal to log(500).
Strata 10 are individuals in the 40-85 years age category and have a lCD40
count of less than log(200). Strata 11 are individuals in the 40-85 years
age category and have a lCD40 count between log(200− 499). Strata 12 are
individuals in the 40-85 years age category and have a lCD40 count greater
than or equal to log(500).
The plot illustrates different hazards for lCD40 categories. Strata with lower
lCD40 showed faster acceleration.
5.3.2 Partition the time axis
The partitioning of the follow-up time into sub-intervals is also an alterna-
tive approach used in modeling covariates with time-varying effects. Since
some covariates violated the PH assumption over the entire follow-up period,
we decide the partition the follow-up period and fit the Cox model for each
partition. In this model, we partitioned the follow-up time into 0-2 months,
2-6 months 6-18 months, 18-40 months and 40-65 months. Results ob-
tained after fitting the Cox regression model for each partitioned follow- up
time is presented in the table below. The table contains the value of the
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hazard ratio, p-values, value of the Schoenfeld residual test and the value of
the global test.
Table 5.5: Results obtained from partitioning the time period.
Covariates Parameters 0-2 2-6 6-18 18-40 40-65
months months months months months
Age
Hazard ratio 0.99 0.99 0.99 1.00 1.00
P-value 0.92 0.14 0.77 0.80 0.22
Schoenfeld test 0.05 0.16 0.16 0.96 0.40
Male
Hazard ratio 1.05 0.84 0.91 1.10 1.00
P-value 0.53 0.00 0.05 0.02 0.94
Schoenfeld test 0.65 0.12 0.39 0.34 0.58
Stage2
Hazard ratio 0.75 0.64 0.61 0.76 0.93
P-value 0.01 < 0.001 < 0.001 < 0.001 0.34
Schoenfeld test 0.75 0.70 0.21 0.71 0.16
Stage3
Hazard ratio 0.80 0.59 0.66 0.74 0.90
P-value 0.01 < 0.001 < 0.001 < 0.001 0.09
Schoenfeld test 0.43 0.02 0.05 0.80 0.93
Stage4
Hazard ratio 1.12 0.71 0.64 0.66 0.80
P-value 0.25 < 0.001 < 0.001 < 0.001 0.004
Schoenfeld test 0.32 < 0.001 0.99 0.83 0.20
lCD40
Hazard ratio 0.73 0.91 1.09 1.09 1.17
P-value < 0.001 0.11 0.11 0.06 0.004
Schoenfeld test 0.47 0.44 0.97 0.03 0.14
Global 0.32 0.001 0.14 0.32 0.14
From Table 5.5 above, the Schoenfeld residual p-value for all the covariates
in the various partitioned follow-up time are insignificant excluding the fol-
lowing covariates; Stage3 and Stage4 in the 0-2 months segment and lCD40
in the 18-40 months segment. This shows that partitioning the follow-up
time increases the probability of covariates in the Cox-model to satisfy the
proportional hazards assumption.
The effect of Age on death is constant for at the 5 intervals but Schoenfeld
residual test indicates non-PH in the first interval. Thus the non-constant
association is very early on. Intervals seem to induce bigger differences in
gender and Stage effects, variables that were deemed to have a constant
effect in the Cox model. The estimates for the effect of lCD4 across the
intervals successively illustrate the decreasing association of baseline logged
CD4,(lCD40) on the relative hazard of death.
Another thing that was observed from the results presented in Table 5.5
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above is that the global test for each partitioned follow-up time met the
proportional assumptions except that of 2-6 months segment.
As discussed in section 4.2.5, the Cox-Snell residual is used in assessing the
overall fit of a model. Hence, we show the Cox-Snell residual for models fitted
on each one of the segments and compare them to the Cox-Snell residuals for
the model fitted on the whole data set where some of the variables violated
the PH assumption. A plot close to the 45o line indicates that the model is
good fit.
Comparing the plot in Figure 5.1 to those in Figure 5.8 below, we see that
the model has a better fit when the time axis is divided into shorter segments
compared to when the model is fitted on the whole time interval of study.
We make this conclusion because each plots in the different time segments
are very close to the 45o line. This proves that if there are covariates that
violate the PH assumption over the entire time interval, splitting the time
axis into smaller segments or partitions and fitting the Cox model in each
partition is a way to handle time-varying coefficients.
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(a) Cox-Snell residual for
follow-up time 0-2 months
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(b) Cox-Snell residual for
follow-up time 2-6 months
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(c) Cox-Snell residual for
follow-up time 6-18 months
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(d) Cox-Snell residual for
follow-up time 18-40 months
0.00 0.02 0.04 0.06 0.08 0.10
0.
00
0.
02
0.
04
0.
06
0.
08
0.
10
0.
12
Residual
Es
tim
at
ed
 C
um
 H
az
ar
ds
(c) Cox-Snell residual for follow-up
time 40-65 months
Figure 5.8: Cox-Snell residuals for the partitioned follow- up times.
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5.3.3 Model non proportionality by time-dependent
covariates
From section 5.2.1.5 where the PH assumption was tested and the covariates
Age and lCD40 violated the assumption. Model non proportionality by time-
dependent covariates is another method for handling covariates that violated
the PH assumption. In this section, various time functions were used in
modelling the covariates, Age and lCD40 since they were found not to remain
the same over time. However, Age was not modelled with any function of
time because its appropriate form was an interaction between the linear form
of time and Age. This essentially means we are modelling time. Hence, the
focus was on lCD40 only.
Table 5.6 below presents the results obtained from modelling the covariate
lCD40 which violated the PH assumption as an interaction between lCD40
and a quadratic form of time.
Table 5.6: Results obtained from modelling non- proportionality by time-
dependent covariates.
Covariate Coef. HR SE p-value
Age 0.029 1.029 0.003 <0.001
Male 0.169 1.184 0.072 0.019
Stage2 0.371 1.449 0.188 0.048
Stage3 1.276 3.581 0.146 <0.001
Stage4 1.719 5.578 0.153 <0.001
lCD40 -1.315 0.269 0.064 <0.001
tt(lCD40) 4.5e-04 1.00045 9.3e-05 <0.001
The row in Table 5.6 titled tt(lCD40) is the measure of the time-varying
effect of the covariate. As mentioned earlier, this was modelled as an in-
teraction term between lCD40 and a quadratic form of time. Comparing
the results from Table 5.6 to that of the Cox regression model in Table 5.1,
even though their coefficients have changed a bit, both models have the same
association trends.
The results in Table 5.6 are interpreted similarly to the results in Table
5.1 except that for the variable lCD40. The lCD40 effect is measured as
−1.315 lCD40 + 0.00045 lCD402.
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5.4 The extended Cox model
As stated in section 4.5, the extended Cox model is an extension of the
Cox proportional hazard regression model used in fitting exogenous time-
varying covariates. Hence, while fitting this model, we made use of the
time-updated data whereas in the Cox PH model, only baseline observations
of covariates are used. This model combines baseline covariates as well as
time-varying covariate. For the Gugulethu data the following variables are
baseline covariates Age, Male, Stage2, Stage3 and Stage4 whereas Tx and
lCD4 are time-varying covariates. The model structure of the model fitted is
as shown below:
hi(t) = h0(t) exp
{
γ1Agei + γ2Malei + γ3Stage2i + γ4Stage3i + γ5Stage4i
+ α1Tx(t) + α2lCD4(t)
}
(5.3)
The results obtained from fitting the model in equation 5.3 is shown in the
table below.
Table 5.7: Results of the extended Cox model.
Covariate Coef. HR SE lower .95 upper .95 p-value
Age 0.03 1.03 0.00 1.027 1.041 <0.000
Male 0.16 1.17 0.07 1.011 1.342 0.031
Stage2 0.24 1.27 0.19 0.881 1.834 0.202
Stage3 0.99 2.70 0.15 2.084 3.689 <0.000
Stage4 1.37 3.92 0.15 3.024 5.488 <0.000
Tx -0.62 0.54 0.09 0.350 0.485 <0.000
lCD4 -1.63 0.20 0.06 0.184 0.232 <0.000
All the covariates in Table 5.7 except for Stage2 have a significant effect on
the risk of death. In addition, the association trends in the extended Cox
are similar to those in the Cox PH model. However, there is a distinction
while interpreting the time-varying covariates such as lCD4 and Tx in the
extended Cox. At any specific time point t, a unit increase in lCD4 results in
about 80% decrease in the risk of death at the same point. For a patient on
treatment at a given time t, the relative hazard of death decreases by about
46%.
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The results below refer to models that were fitted including each of the time-
varying covariates one at a time to allow for comparison with Cox PH model
and future joint models.
Table 5.8: Results of the extended Cox model.
Covariate Coef. HR SE lower .95 upper .95 p-value
Age 0.03 1.03 0.00 1.027 1.041 <0.000
Male 0.16 1.17 0.07 1.016 1.348 0.030
Stage2 0.23 1.26 0.19 0.871 1.814 0.222
Stage3 0.99 2.70 0.15 2.029 3.592 <0.000
Stage4 1.35 3.86 0.15 2.867 5.201 <0.000
lCD4 -1.67 0.19 0.06 0.168 0.211 <0.000
The covariate lCD4 is strongly associated with the risk of death with a unit
increase in the logged CD4 resulting to about 81% decrease in the risk of
death. From Table 5.8 below, the impact of time-updated lCD4 is stronger
than that of baseline lCD40 as modelled using the Cox PH model see table
5.1. In the Cox PH model, a unit increase in the logged value of the baseline
CD4 resulted in about 69% decrease in the risk of death. This is because,
in the Cox PH model only one observation is used in modelling the lCD40,
that is the baseline lCD4. However, in the extended Cox model, the lCD4
measurements are updated each time follow up time and this provides more
and better information thus leading to more reliable results.
Table 5.9: Results of the extended Cox model.
Covariate Coef. HR SE lower .95 upper .95 p-value
Age 0.03 1.03 0.00 1.025 1.038 <0.000
Male 0.29 134 0.07 1.160 1.537 <0.000
Stage2 0.44 1.55 0.19 1.073 2.233 0.020
Stage3 0.39 4.00 0.14 3.017 5.313 <0.000
Stage4 1.98 7.27 0.15 5.430 9.728 <0.000
Tx -0.85 0.43 0.09 0.359 0.508 <0.000
The results from Table 5.9 shows that there is a significant decrease in the
risk of death at a given time t by about 57% for a patient on treatment at
the same time compared to a patient who is not on treatment.
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5.5 The Joint model
Unlike the extended Cox model that is suitable for analysing exogenous time-
varying covariates. The joint model is appropriate for modelling the asso-
ciation between endogenous time-dependent covariates and time-to-event as
discussed in section 4.6. The dataset used in this research has two longitudi-
nal outcome variables: lCD4 and Tx that are endogenous to the process being
analysed. Hence, we fit univariate joint models for each of the longitudinal
outcome variables.
The results obtained from fitting a univariate joint model for the effect of
lCD4 is presented in Table 5.10.
Table 5.10: A univariate joint model for the effect of lCD4.
Survival Outcome
PostMean 95% CI exp(postmean) p-value
Age 0.0122 0.0012, 0.0231 1.0123 0.022
Male 0.2605 0.0556, 0.4593 1.2976 0.016
Stage2 0.3290 -0.4002, 1.1219 1.3896 0.348
Stage3 1.5876 1.0582, 2.1716 4.8920 <0.000
Stage4 2.0787 1.5555, 2.6665 7.9941 <0.001
lCD4value -2.0157 -2.205, -1.8098 0.1332 <0.001
Longitudinal Outcome
PostMean 95% CI p-value
Intercept 2.1759 2.1685, 2.1830 <0.001
Time 0.0238 0.0234, 0.0241 <0.001
sqTime -0.0003 -0.0003, -0.0003 <0.001
sigma 0.1776 0.1768, 0.1785 <0.001
From the results for the survival outcome, presented Table 5.10, the param-
eter lCD4value is the parameter that measures the degree of relationship
and association between lCD4 and the risk of death. Hence, from the results
there is a strong relationship between lCD4 and the risk of death with a unit
increase in lCD4 resulting to about 87% decrease in the relative risk of death.
Comparing the results obtained from the extended Cox which included only
one longitudinal outcome lCD4 that was presented in Table 5.8 above, it
was observed that the association between the lCD4 and the risk of death is
stronger in the joint model compared to the extended Cox model.
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Table 5.11 presents the results obtained from fitting a univariate joint model
for the effect of treatment.
Table 5.11: A univariate joint model for the effect of treatment.
Survival Outcome
PostMean 95% CI exp(postmean) p-value
Age 0.0126 0.0028, 0.0220 1.0127 0.012
Male 0.4494 0.2263, 0.6687 1.5674 <0.000
Stage2 0.3848 -0.3434, 1.1097 1.4693 0.310
Stage3 1.9432 1.4387, 2.5782 6.9811 <0.000
Stage4 2.8486 2.3584, 3.4401 17.2636 <0.001
Txvalue -0.2636 -0.3037, -0.2212 0.7683 <0.001
Longitudinal Outcome
PostMean 95% CI p-value
Intercept -0.2330 -0.2919, -0.1755 <0.001
Time 0.2815 0.2718, 0.2911 <0.001
From the results presented in Table 5.11, there is a strong relationship be-
tween Tx and the risk of death with about 77% decrease in the risk of death
for those on treatment when compared to those who are not on treatment.
Comparing the results obtained in Table 5.11 to that obtained in Table 5.9,
the degree of relationship between Tx and the risk of death is suppressed in
the latter model compared to the former. This shows that the extended Cox
model does not handle endogenous time-varying covariates appropriately.
5.6 Extensions of the Joint model
In the standard joint model, we assumed that the an association parameter
measures the degree of association between the longitudinal outcome at a
specific time point t and the risk of event at the same time point. However,
this assumption may not be feasible all the time. Hence, in this section,
the degree of association between the longitudinal outcome and the risk of
event is modelled using different parametrization structure. In addition, a
bivariate joint model that measures the degree of association between two
longitudinal outcome (lCD4 and Tx) and the risk of death is fitted.
The interaction effect parametrization is used to measure the degree of asso-
ciation between a longitudinal outcome and the risk of event in subgroups.
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Hence, Table 5.12 below shows the results from models fitted to measure the
degree of association between the longitudinal outcomes lCD4 and the risk
of event in the gender subgroup.
Table 5.12: Results obtained from the univariate joint model on the interaction
effect in the gender subgroup for lCD4.
Survival Outcome
PostMean 95% CI exp(PostMean) p-value
Age 0.0132 0.0006, 0.0249 1.0133 0.046
Male -0.8824 -1.6582, -0.1295 0.04138 0.030
Stage2 0.4331 -0.3458, 1.2065 1.5420 0.274
Stage3 1.6247 1.0288, 2.3008 5.0769 <0.001
Stage4 2.1465 1.5213, 2.8320 8.5549 <0.001
lCD4value -2.2893 -2.5984, -1.9711 0.1013 <0.001
lCD4value:Male 0.6785 0.2565, 1.1121 1.9709 0.006
Longitudinal Outcome
PostMean 95% CI p-value
Intercept 2.1759 2.1684, 2.1833 <0.001
Time 0.0238 0.0234, 0.0241 <0.001
sqTime -0.0003 -0.0003, -0.0003 <0.001
sigma 0.1776 0.1767, 0.1785 <0.001
lCD4 is strongly related with the risk of death. Each unit increase in the
current value of lCD4 is associated with about 90% decrease in the risk of
death for those who are females and about 80% decrease in the risk of death
for those who are males. From the results, the degree of association between
lCD4 and the risk of death for the gender subgroup is different.
In the time-dependent slopes parametrization structure, the risk of an event
depends on the current value and slope of the longitudinal trajectory. Table
5.13 present results from the time-dependent slopes parametrization on the
lCD4 longitudinal trajectory.
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Table 5.13: Results obtained from the univariate joint model on the time depen-
dent slopes for lCD4
Survival Outcome
PostMean 95% CI exp(PostMean) p-value
Age 0.0113 0.0000, 0.0241 1.0114 0.050
Male 0.2613 0.0424, 0.4906 1.2986 0.016
Stage2 0.3307 -0.4352, 1.0841 1.3919 0.390
Stage3 1.5983 1.0537, 2.2689 4.9446 <0.001
Stage4 2.0926 1.5655, 2.7692 8.1060 <0.001
lCD4value -2.7613 -5.3843, 0.4528 0.0632 0.074
lCD4slope 0.7857 -2.4739, 3.5114 2.1939 0.562
Longitudinal Outcome
PostMean 95% CI p-value
Intercept 2.1759 2.1684, 2.1833 <0.001
Time 0.0238 0.0234, 0.0241 <0.001
sqTime -0.0003 -0.0003, -0.0003 <0.001
sigma 0.1776 0.1767, 0.1785 <0.001
From Table 5.13, it can be seen observed that the slope of the trajectory is
not associated with the risk of death, (p=0.562). However, the log hazard
ratio for a unit increase in the current slope of the lCD4 trajectory is 0.7857
for patients with the same lCD4 value. This is not significant.
The cumulative effect parametrization is based on the assumption that the
risk of an event depends on the cumulative trajectory of the longitudinal
outcome. Hence, we are interested in knowing the degree of relationship
between the risk of event and the cumulative longitudinal trajectory. Table
5.14 presents the results of modelling the degree of relationship between the
risk of death and the cumulative longitudinal trajectory of lCD4.
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Table 5.14: Results obtained from the univariate joint model on the cumulative
effect for lCD4
Survival Outcome
PostMean 95% CI exp(PostMean) p-value
Age 0.0126 0.0024 0.0234 1.0268 0.018
GenderMale 0.3797 0.1432 0.6003 1.4618 0.004
Stage2 0.5088 -0.2844 1.2437 1.6633 0.194
Stage3 1.9479 1.3926 2.5006 7.0139 <0.001
Stage4 2.6348 2.1023 3.2332 13.9405 <0.001
lCD4Area -0.3698 -0.4296 -0.3067 0.6909 <0.001
Longitudinal Outcome
PostMean 95% CI p-value
Intercept 2.1759 2.1684 2.1833 <0.001
Time 0.0238 0.0234 0.0241 <0.001
sqTime -0.0003 -0.0003 -0.0003 <0.001
sigma 0.1776 0.1767 0.1785 <0.001
From Table 5.14 above, there is a strong relationship between lCD4 and the
risk of death with a unit increase in the area under the log CD4 (lCD4)
longitudinal profile resulting to a decrease in the risk of death.
5.7 Joint models for multiple longitudinal re-
sponses.
Joint models for multiple longitudinal responses was introduced in 4.6.5.
This model accommodates multivariate longitudinal responses of different
distribution types in a unified framework. In the Gugulethu HIV/AIDS data
used in this analysis, two longitudinal responses of interest in predicting the
risk of death are lCD4 and Tx. The joint models for multiple longitudinal
responses was used in fitting the longitudinal responses of interest. lCD4 and
Tx were modelled using the gaussian and binomial distributions respectively.
The result for the fitted model is presented in Table 5.15 below.
805.7. JOINT MODELS FOR MULTIPLE LONGITUDINAL RESPONSES.
Table 5.15: A bivariate joint model for treatment and CD4.
Survival Outcome
PostMean 95% CI exp(postmean) p-value
Age 0.0219 0.0071, 0.0370 1.0221 0.010
Male 0.1733 -1.227, 0.4734 1.1892 0.298
Stage2 0.0605 -1.1334, 1.1151 1.0624 0.886
Stage3 1.7041 1.0367, 2.4353 5.4964 <0.000
Stage4 2.4392 1.7548, 3.1901 11.4639 <0.001
lCD4value -1.9710 -2.27887, -1.6688 0.1393 <0.001
Txvalue -0.4437 -0.5268, -0.3662 0.6417 <0.001
Longitudinal Outcome
lCD4 PostMean 95% CI p-value
Intercept 2.1752 2.1659, 2.1829 <0.001
Time 0.0237 0.0233, 0.0247 <0.001
sqTime -0.0003 -0.0003, -0.0003 <0.001
sigma 0.1776 0.1767, 0.1786 <0.001
Longitudinal Outcome
Tx PostMean 95% CI p-value
Intercept -0.0227 -0.0657, 0.0185 0.302
Time 0.2385 0.2334, 0.2436 <0.001
From Table 5.15, lCD4value and Txvalue have significant effect on the risk
of death with a unit increase in lCD4 resulting to in about 86% decrease in
the risk of death. In addition, there is about 36% decrease in the risk of death
for patients on treatment compared to parents who are not on treatment.
Comparing the results in Table 5.7 which is an extended Cox model that
estimates the effect of lCD4 and Tx to the risk of death to results presented
in Table 5.15 which is a bivariate joint model for lCD4 and Tx. In the lat-
ter model, there is a higher percentage in the decrease in the risk of death
compared to the former for a unit increase in lCD4. On the other hand,
the percentage decrease in the risk of death for patients on treatment com-
pared to patients that are not on treatment is higher in the extended Cox
model compared to the bivariate joint model. The extended Cox model as-
sumes step-wise updating of values at the observed time points while the joint
model allows for a smoothed underlying change. This is more appropriate
for the lCD4 profiles than for the Tx profile, since the latter is essentially a
discrete process where a patient is either off or on the treatment. Under the
assumption that treatment initiation happened between visits, the smoothed
Tx will be appropriate.
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5.8 The Aalen model
In section 4.7, we reviewed the Aalen’s additive hazard model as one of
the approaches used in handling time-varying covariate coefficients. In this
section, we will examine the effect the following covariates of interest; Age,
Male, Stage2, Stage3, Stage4, treatment and log(CD4) have on survival
using the Aalen’s additive hazard model. This will be applied to the baseline
and time-updated Gugulethu dataset. The model will be fitted using the
timereg package in R.
5.8.1 Aalen’s additive hazard regression model applied
to the baseline covariates of the Gugulethu dataset.
In this section, we fit the additive hazards model while applying it to the
baseline covariates of the Gugulethu HIV/AIDS dataset. In this framework
we assume that all the covariates inclded in the model have non-parametric
time-varying effects. The model is fitted with Age, Male, Stage2, Stage3,
Stage4 and the logged baseline CD4 count (log(CD40)).
The fitted model is as shown below:
h(t) = β0(t) + β1(t) Age + β2(t) Male + β3(t) Stage2 + β4(t)Stage3
+ β5(t) Stage4 + β7(t) lCD40 (5.4)
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Table 5.16: Tests associated with the Aalen’s additive hazard regression model
on the HIV baseline data.
Test for non-significant effect Test for time-invariant effects
Covariates Statistic p-value Statistic p-value
Intercept 11.20 <0.001 0.209 <0.001
Age 7.40 <0.001 <0.001 0.580
Male 4.02 0.003 0.014 0.275
Stage2 4.71 <0.001 0.012 0.229
Stage3 7.95 <0.001 0.014 0.238
Stage4 9.50 <0.001 0.058 <0.001
lCD40 13.60 <0.001 0.088 <0.001
The output in Table 5.16 presents a two sets of summary statistics namely,
the supremum test of significance used to verify if covariates have significant
effect on the event of interest and the Kolmogorov-Smirnov test of constant
effect used in checking if covariates have time-varying coefficients. All the
covariates had significant effects on the risk of death. Two covariates indi-
cated evidence of time-varying effects. They are Stage4 and lCD40 whereas
the other covariates (Age, Male, Stage2, Stage3) appeared to have constant
effect with time.
The plots in Figure 5.9 shows the estimated cumulative regression coefficients
against time with 95% pointwise confidence intervals. This figure confirms
the statistics presented in Table 5.16 as all the variables with constant time
effect had their estimated cumulative function being approximately straight
lines showing a constant slope, whereas those with time varying effects change
slopes, often fast initially and slows down later. This is seen from figure 5.9
since all the confidence bands for all the variables other than lCD40 and
Stage4 cross zero. lCD40 has a negative slope indicating that an increase in
these covariates results in a decrease in the relative hazard of death. On the
other hand, Stage4 has a positive slope indicating that subjects with Stage4
HIV/AIDS have an increased risk of death compared to subjects with Stage1
HIV/AIDS.
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Figure 5.9: Estimated cumulative regression functions with 95% pointwise confi-
dence intervals based on Aalen’s additive model - baseline HIV data.
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5.8.2 Inference for additive hazard models
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Figure 5.10: Estimated cumulative regression functions with 95% pointwise con-
fidence intervals(solid lines), Hall-Wellner bands (broken lines)
and simulation based bands(dotted lines) - baseline Gugulethu
HIV/AIDS data.
The pointwise confidence intervals in figure 5.10 will be used for comparison.
The zero-function is observed to be outside the bands for both the Hall-
Wellner band and the simulation based band showing that the time-varying
effects of Stage4 and lCD40 are significant.
Considering the estimates depicted in Figure 5.9 it is not clear based on
the pointwise confidence interval shown there which of the components that
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have time-varying effects. Figure 5.10 shows three sets of confidence bands
and more clearly illustrates that only the confidence bands for Stage4 and
lCD40 excludes zero. However, the bands do not reflect the uncertainty of
the estimate of the constant effect. It is seen that the intercept, Stage4 and
lCD40 do have effects that vary with time. Figure 5.11 below are plots of
the processes with 50 random realizations under the null of constant effects
for all the variables.
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Figure 5.11: Test processes for testing constant effects with 50 simulated pro-
cesses under the null - baseline HIV data.
In Figure 5.11, the grey lines are the 50 simulated processes under the null
hypothesis used in testing for constant effects of the covariates. When the
black solid line is outside the grey lines, that covariate is said to have a time-
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varying effect. Hence, the intercept, Stage4 and lcd40 have time-varying
effect while the other covariates have performances consistent with the null of
time-invariant effect. As seen from the simulation based results in Table 5.16,
the p-value was < 0.001 for the intercept, 0.580 for Age, 0.275 for Male,
0.229 for Stage2, 0.238 for Stage3, < 0.001 for Stage4, < 0.001 for lCD40.
Thus, we reject the hypothesis of constant effect for intercept, Stage4 and
lCD40.
The results presented in Table 5.16 was obtained after fitting model specified
in equation 5.4 and it showed that not all the covariates had time-varying
effects. Hence, a number of successive test will be performed in order to
achieve a parsimonous and best fitted model. First, we note that the Male
does not seem to have a time-varying effect (p=0.580, using the test of time-
invariant effects), which, as mentioned before, is consistent with the cumu-
lative estimate being approximately a straight line in Figure 5.9. Fitting
the model with the effect of Male being constant (output can be found in
the Appendix A) we found that the effects of Age, Stage2 and Stage3 were
also constant (p=0.564, 0.174, 0.143) respectively. Secondly, the model with
both Male and Age having constant effects showed that the effect of Stage2
and Stage3 were constant also (p=0.197 and 0.191). Thirdly, a model with
Male, Age and Stage2 having constant effects was fitted. Finally, a reduced
semi-parametric model was fitted with the covariates Male, Age, Stage2 and
Stage3 having constant effects. The result is presented below.
Table 5.17: Test associated with the semi-parametric hazard regression model
on the HIV baseline data.
Tests for non-significant effect Test for time-invariant effects
Covariates Statistic p-value Statistic p-value
Intercept 14.00 <0.001 0.227 <0.001
Stage4 9.43 <0.001 0.053 <0.001
lcd40 14.20 <0.001 0.092 <0.001
Parametric
terms Coeff SE 95% CI p-value
const(Age) 5.13e-05 7.93e-06 3.58e-05, 6.68e-05 <0.001
const(Male) 7.63e-04 1.91e-04 3.89e-04, 1.14e-03 <0.001
const(Stage2) -2.44e-05 1.67e-04 -3.52e-04, 3.03e-04 0.886
const(Stage3) 1.19e-03 1.68e-04 8.61e-04, 1.52e-03 <0.001
The fit of the semi-parametric model shows that Stage4 and lCD40 have
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effects that are significantly time-varying (p<0.001 for all of them) using the
test of time invariant effects. The effect of the other covariates is described
by their constant effects. What is interesting to observe is how small the
effects of the constant terms are. They are of course now additive effects as
oppose to multiplicative effects. The time-varying effects are illustrated in
figure 5.12 and are as estimated in previous models.
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Figure 5.12: Estimated cumulative regression functions with 95% pointwise con-
fidence intervals based on Aalen’s semi-parametric additive model
- baseline HIV data.
5.8.3 Aalen’s additive regression model applied to the
time-updated Gugulethu data
Similar procedures applied to the Gugulethu HIV/AIDS baseline dataset
will be carried out here except that they will be applied to different datasets.
Here, the HIV time updated data will be used. The aim is to examine the
effect of each covariate on survival. I commenced with the additive hazards
model framework where all components of the model have nonparametric
time-varying effects.
The fitted model is as shown below:
h(t) = β0(t) + β1(t) Age + β2(t) Male + β3(t) Stage2 + β4(t)Stage3 + β5(t) Stage4
+ β6(t) Tx(t) + β7(t) lCD4(t) (5.5)
Results from the tests for non-significant effects and time-invariant effect are
presented in Table 5.18 on the time updated HIV data. All the covariates
excluding the covariate Male had significant effects on the risk of death. On
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Table 5.18: Tests associated with the Aalen’s additive hazard regression model
on the HIV time updated data.
Test for non-significant effects Test for time-invariant effects
Covariates Statistic p-value Statistic p-value
Intercept 12.30 <0.001 0.179 0.062
Age 3.37 0.019 0.001 0.620
Male 2.89 0.084 0.013 0.265
Stage2 4.83 <0.001 0.012 0.239
Stage3 7.82 <0.001 0.013 0.280
Stage4 9.70 <0.001 0.057 <0.000
Tx 5.75 <0.001 0.066 0.339
lCD4 13.60 <0.001 0.074 <0.000
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Figure 5.13: Estimated cumulative regression functions with 95% pointwise con-
fidence intervals based on Aalen’s additive model - time-updated
HIV data.
the other hand, the covariates Stage4 and lCD4 indicate evidence of time-
varying effects while other covariates (Age, GenderMale, Stage2, Stage3, Tx)
appeared to have effects that is constant with time.
Figure 5.13 above is a plot showing the estimated cumulative regression coef-
ficients with 95% pointwise confidence intervals. A careful look at this figure
shows some estimated cumulative functions with approximately straight lines
and others are not. They covariates with their estimated cumulative func-
tions being approximately straight lines are Age, Male, Stage2, Stage3, Tx.
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These covariates are said to have constant time effects while the other co-
variates Stage4 and lCD4 are said to have time varying effects since their
estimated cumulative functions are not straight lines. This conforms with
the statistics presented in Table 5.18.
5.8.4 Inference for additive hazard models
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Figure 5.14: Estimated cumulative regression functions with 95% pointwise con-
fidence intervals(solid lines), Hall-Wellner bands (broken lines) and
simulation based bands(dotted lines) - time-updated HIV data.
Figure 5.14 above will be used to draw inference on the Aalen additive hazard
model fitted to the updated HIV data. The pointwise confidence interval will
be used in making comparison. Stage4 and lCD4 had their zero-functions
outside the bands for both the Hall-Wellner band and the simulation based
band showing that the time-varying effects are significant. Contrariwise,
Age, GenderMale, Stage2, Stage3 and Tx zero-functions inside the bands for
both the Hall-Wellner band and the simulation based band depeting their
time-invariant effects.
From Figure 5.15 we can reject the hypothesis of constant effect for Stage4
and lCD4 while the other covariates have performances consistent with the
null of time-invariant effect.
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Figure 5.15: Test processes for testing constant effects with 50 simulated pro-
cesses under the null - time updated HIV data.
At this point, it is obvious that some of the variables are time-invariant
while others have time-varying effects. Hence, we will move ahead to sim-
plify the model as shown below. First, we note that the Age does not seem to
have a time-varying effect (p=0.620, using the test of time-invariant effects),
which, as mentioned before, is consistent with the cumulative estimate being
approximately a straight line in Figure 5.13. Fitting the model with the ef-
fect of Age being constant (output can be found in the Appendix) we found
that the effects of Male, Stage2, Stage3and Tx were also constant (p=0.217,
0.229, 0.308, 0.377) respectively. Secondly, the model where both Age and
Tx have constant effects showed that the effect of Male, Stage2 and Stage3
were constant also (p=0.172,0.190 and 0.263). Thirdly, a model with Age,
Tx and Stage3 having constant effects was fitted and Male and Stage2 was
found to have constant effects (p= 0.121 and < 0.001) respectively. Fourthly,
a model with Age, Tx, Stage3 and Male having constant effects was fitted
and Stage2 was found to have a time-varying effect (p= < 0.001). Finally, a
reduced semi-parametric model was fitted with the covariates Male, Tx, Age,
Stage2 and Stage3 having constant effects. The result is presented below.
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Table 5.19: Test associated with the semi-parametric hazard regression model
on the HIV time updated data.
Tests for non-significant effect Test for time-invariant effects
Covariates Statistic p-value Statistic p-value
Intercept 14.30 <0.001 0.189 0.003
Stage4 9.92 <0.001 0.054 <0.001
lCD4 14.10 <0.001 0.079 0.001
Parametric terms
Coeff SE 95% CI p-value
const(Age) 2.66e-05 8.30e-06 1.03e-05, 4.29e-05 0.001
const(Male) 5.77e-04 1.91e-04 2.03e-04, 9.51e-04 0.004
const(Stage2) 3.61e-06 1.67e-04 -3.24e-04, 3.31e-04 0.983
const(Stage3) 1.25e-03 1.66e-04 9.25e-04, 1.58e-03 <0.001
const(Tx) -1.85e-03 3.33e-04 -2.50e-03, -1.20e-03 <0.001
The fit of the semi-parametric model shows that Stage4 and lCD4 have effects
that are significantly time-varying (p <0.001 for both covariates) using the
test of time invariant effects. Increasing Age by a year, results in a significant
increase in the risk of death by 2.66e-05 (se=6.57e-06). In addition, Males
have significant increased intensity of 5.77e-04 (se=1.91e-04) when compared
to females. Patients with HIV/AIDS status in Stage2 and Stage3 have
an estimated increased risk of death of 3.61e-06 and 1.25e-03 respectively
compared to patients with HIV/AIDS status in Stage1. Furthermore, Tx
has a reduced estimated risk of death of -1.85e-03 (se=3.33e-04).
The effect of the time-updated lCD4 values was estimated to be time-varying
too. Hence, even when using the time-updated current lCD4, the impact is
larger during early follow-up period compared to later follow-up period.
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Figure 5.16: Estimated cumulative regression functions with 95% pointwise con-
fidence intervals based on Aalen’s semi-parametric additive model-
time updated HIV data.
Chapter 6
Conclusions
In this dissertation, various approaches for handling time-varying coefficients
and covariates in longitudinal and survival models were investigated. Each
model discussed in Chapter 4 was applied to the Gugulethu HIV/AIDS data.
This research commenced by fitting the popular model used in analysing
survival data, the Cox PH model and checking the PH assumption. Co-
variates that violate the PH assumption are said to have time-varying ef-
fects/coefficients. This led to fitting models that handle time-varying coeffi-
cients. They include stratified Cox model, partitioning the time period and
modelling non-proportionality by time-dependent covariates.
The limitation of the stratified Cox model is that estimates are not obtained
for the stratifying variable. Hence, the magnitude of their effect is unknown
for the stratified variable. Partitioning of the time period seem to give more
reliable results as different Cox models are fitted on smaller segments of
the follow-up period. However, this approach demands a motivation for
which a particular time interval is chosen. Another approach is to model
non-proportionality by time-dependent covariates but the limitation of this
method is that the validity of the results obtained from the model depends
on the appropriateness of the selected function of time.
Furthermore, models were fitted to incorporate covariates that were time-
varying. These include the extended Cox model, the joint model and its ex-
tensions, the Aalen model and the semi-parametric additive model. The ex-
tended Cox model handled exogenous time-varying covariates adequately but
performed poorly in modelling endogenous time-varying covariates. Hence,
the joint model and its extensions were used instead as they gave more accu-
rate results for the estimate of effects of endogenous time-varying variables.
The results from the extensions of the joint model were more precise com-
pared to the standard joint model. This is because, the assumptions for each
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of those extensions handled specific situations that were not incorporated
in the standard joint model. In contrast to the models that have been fit-
ted, the Aalen model is an additive model that analysis survival data with
time-varying covariates as well as time-varying coefficients.
The semi-parametric additive model gives more precise results when com-
pared to the Aalen model because the former assumes that all the covariates
have time-varying effects which is not always the case while the former takes
into cognisance the fact that some variables could have constant effect. The
beauty of the Aalen model and the semi-parametric additive model is that the
effect of variables with both time varying effects and time varying covariates
can be modelled and measured.
Other models that could be explored include the Cox-Aalen model (Marti-
nussen and Scheike, 2007) which is an alternative model that combines Cox
proportional hazards model for covariates with constant effects and the Aalen
additive model for time-varying effects in a single model. The dynamic path
model (Gamborg et al., 2011) which combines path analysis and survival
analysis in order to estimate the effect of covariates on the risk of an event.
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Appendix A
Additional Tables and Plots
This chapter contains additional results from the models fitted in this re-
search presented in tables as well as plots that were generated.
Table A.1: Test associated with the semi-parametric hazard regression model on
the HIV baseline data with the effect of the covariate male fitted to
be time-invariant.
Tests for non-significant effect Test for time-invariant effects
Covariates Statistic p-value Statistic p-value
Intercept 11.30 <0.001 0.210 <0.001
Age 7.37 <0.001 0.001 0.564
Stage2 4.50 <0.001 0.013 0.174
Stage3 7.93 <0.001 0.015 0.143
Stage4 9.63 <0.001 0.059 <0.001
lcd40 13.60 <0.001 0.088 <0.001
Parametric
terms Coeff SE 95% CI p-value
const(Male) 7.41e-04 1.91e-04 3.67e-04, 1.12e-03 <0.001
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Table A.2: Test associated with the semi-parametric hazard regression model on
the HIV baseline data with the effect of the covariates male and Age
fitted to be time-invariant.
Tests for non-significant effect Test for time-invariant effects
Covariates Statistic p-value Statistic p-value
Intercept 13.30 <0.001 0.218 <0.001
Stage2 4.62 <0.001 0.012 0.197
Stage3 7.95 <0.001 0.015 0.191
Stage4 9.64 <0.001 0.059 <0.001
lcd40 13.90 <0.001 0.089 <0.001
Parametric
terms Coeff SE 95% CI p-value
const(Age) 5.08e-05 7.92e-06 3.53e-05, 6.63e-05 <0.001
const(Male) 7.52e-04 1.91e-04 3.78e-04, 1.13e-03 <0.001
Table A.3: Test associated with the semi-parametric hazard regression model on
the HIV baseline data with the effect of the covariates male, Age and
Stage2 fitted to be time-invariant.
Tests for non-significant effect Test for time-invariant effects
Covariates Statistic p-value Statistic p-value
Intercept 13.30 <0.001 0.214 <0.001
Stage3 7.20 <0.001 0.018 0.010
Stage4 9.52 <0.001 0.062 <0.001
lcd40 13.90 <0.001 0.089 <0.001
Parametric
terms Coeff SE 95% CI p-value
const(Age) 5.06e-05 7.92e-06 3.51e-05, 6.63e-05 <0.001
const(Male) 7.47e-04 1.91e-04 3.73e-04, 1.12e-03 <0.001
const(Stage2) -1.15e-04 1.67e-04 -4.42e-04, 2.12e-04 <0.001
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Table A.4: Test associated with the semi-parametric hazard regression model on
the HIV time updated data with the effect of the covariate Age fitted
to be time-invariant.
Tests for non-significant effect Test for time-invariant effects
Covariates Statistic p-value Statistic p-value
Intercept 13.90 <0.001 0.192 0.045
Male 3.00 0.071 0.014 0.217
Stage2 4.84 <0.001 0.012 0.229
Stage3 7.80 <0.001 0.013 0.308
Stage4 9.71 <0.001 0.057 <0.001
Tx 5.73 <0.001 0.0540 0.377
lCD4 14.00 <0.001 0.076 0.003
Parametric terms
Coeff SE 95% CI p-value
const(Age) 2.38e-05 8.27e-06 7.59e-06, 4e-05 3.18e-03
Table A.5: Test associated with the semi-parametric hazard regression model on
the HIV time updated data with the effect of the covariates Age and
Tx fitted to be time-invariant.
Tests for non-significant effect Test for time-invariant effects
Covariates Statistic p-value Statistic p-value
Intercept 13.70 <0.001 0.177 0.007
Male 3.14 0.036 0.014 0.172
Stage2 4.92 <0.001 0.012 0.190
Stage3 8.21 <0.001 0.013 0.263
Stage4 9.89 <0.001 0.057 <0.001
lCD4 13.80 <0.001 0.077 <0.001
Parametric terms
Coeff SE 95% CI p-value
const(Age) 2.56e-05 8.28e-06 9.37e-06, 4.18e-05 1.54e-03
const(Tx) -1.79e-03 3.32e-04 -2.44e-03, -1.14e-03 <0.001
101
Table A.6: Test associated with the semi-parametric hazard regression model on
the HIV time updated data with the effect of the covariates Age,
Stage3 and Tx fitted to be time-invariant.
Tests for non-significant effect Test for time-invariant effects
Covariates Statistic p-value Statistic p-value
Intercept 14.00 <0.001 0.186 0.003
Male 3.34 0.033 0.015 0.121
Stage2 5.77 <0.001 0.020 <0.001
Stage4 10.30 <0.001 0.049 <0.001
lCD4 13.90 <0.001 0.078 <0.001
Parametric terms
Coeff SE 95% CI p-value
const(Age) 2.57e-05 8.28e-06 9.47e-06 4.19e-05 1.51e-03
const(Stage3) 1.28e-03 1.70e-04 9.47e-04 1.61e-03 <0.001
const(Tx) -1.81e-03 3.33e-04 -2.46e-03 -1.16e-03 <0.001
Table A.7: Test associated with the semi-parametric hazard regression model on
the HIV time updated data with the effect of the covariates Age,
Gender, Stage3 and Tx fitted to be time-invariant.
Tests for non-significant effect Test for time-invariant effects
Covariates Statistic p-value Statistic p-value
Intercept 14.30 <0.001 0.191 0.004
Stage2 5.76 <0.001 0.020 <0.001
Stage4 10.40 <0.001 0.050 <0.001
lCD4 14.10 <0.001 0.079 <0.001
Parametric terms
Coeff SE 95% CI p-value
const(Age) 2.67e-05 8.31e-06 1.04e-05 4.30e-05 1.03e-03
const(Male) 5.79e-04 1.91e-04 2.05e-04 9.53e-04 4.24e-03
const(Stage3) 1.30e-03 1.69e-04 9.69e-04 1.63e-03 <0.001
const(Tx) -1.86e-03 3.33e-04 -2.51e-03 -1.21e-03 <0.001
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Figure A.1: Martingale residuals for the continuous variables in the extended
Cox model.
